<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:45:29Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4446210" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4446210</identifier>
        <datestamp>2015-06-09</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4446210</article-id>
              <article-id pub-id-type="pmcid">PMC4446210</article-id>
              <article-id pub-id-type="pmc-uid">4446210</article-id>
              <article-id pub-id-type="pmid">26018967</article-id>
              <article-id pub-id-type="pmid">26018967</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0127246</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-14-46586</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma</article-title>
                <alt-title alt-title-type="running-head">Neuroblastoma Trial of Oral DFMO</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Saulnier Sholler</surname>
                    <given-names>Giselle L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gerner</surname>
                    <given-names>Eugene W.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bergendahl</surname>
                    <given-names>Genevieve</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>MacArthur</surname>
                    <given-names>Robert B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>VanderWerff</surname>
                    <given-names>Alyssa</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ashikaga</surname>
                    <given-names>Takamaru</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bond</surname>
                    <given-names>Jeffrey P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ferguson</surname>
                    <given-names>William</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Roberts</surname>
                    <given-names>William</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff007">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wada</surname>
                    <given-names>Randal K.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff008">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Eslin</surname>
                    <given-names>Don</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff009">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kraveka</surname>
                    <given-names>Jacqueline M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff010">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kaplan</surname>
                    <given-names>Joel</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff011">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mitchell</surname>
                    <given-names>Deanna</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Parikh</surname>
                    <given-names>Nehal S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff012">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Neville</surname>
                    <given-names>Kathleen</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff013">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sender</surname>
                    <given-names>Leonard</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff014">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Higgins</surname>
                    <given-names>Timothy</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kawakita</surname>
                    <given-names>Masao</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff015">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hiramatsu</surname>
                    <given-names>Kyoko</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff015">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moriya</surname>
                    <given-names>Shun-suke</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff015">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bachmann</surname>
                    <given-names>André S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff016">
                    <sup>16</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Helen DeVos Children’s Hospital, Grand Rapids, Michigan, United States of America</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>College of Human Medicine, Michigan State University, Grand Rapids, Michigan, United States of America</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Cancer Prevention Pharmaceuticals, Tucson, Arizona, United States of America</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Medical Biostatistics, University of Vermont, Burlington, Vermont, United States of America</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Department of Microbiology and Molecular Genetics, University of Vermont College of Medicine, Burlington, Vermont, United States of America</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Cardinal Glennon Children's Hospital, St. Louis, Missouri, United States of America</addr-line>
              </aff>
              <aff id="aff007">
                <label>7</label>
                <addr-line>University of California San Diego School of Medicine and Rady Children's Hospital, San Diego, California, United States of America</addr-line>
              </aff>
              <aff id="aff008">
                <label>8</label>
                <addr-line>Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States of America</addr-line>
              </aff>
              <aff id="aff009">
                <label>9</label>
                <addr-line>Arnold Palmer Hospital for Children, Orlando, Florida, United States of America</addr-line>
              </aff>
              <aff id="aff010">
                <label>10</label>
                <addr-line>Medical University of South Carolina, Charleston, South Carolina, United States of America</addr-line>
              </aff>
              <aff id="aff011">
                <label>11</label>
                <addr-line>Levine Children's Hospital, Charlotte, North Carolina, United States of America</addr-line>
              </aff>
              <aff id="aff012">
                <label>12</label>
                <addr-line>Connecticut Children's Medical Center, Hartford, Connecticut, United States of America</addr-line>
              </aff>
              <aff id="aff013">
                <label>13</label>
                <addr-line>Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States of America</addr-line>
              </aff>
              <aff id="aff014">
                <label>14</label>
                <addr-line>Children’s Hospital of Orange County, Orange, California, United States of America</addr-line>
              </aff>
              <aff id="aff015">
                <label>15</label>
                <addr-line>Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan</addr-line>
              </aff>
              <aff id="aff016">
                <label>16</label>
                <addr-line>University of Hawaii at Hilo, The Daniel K. Inouye College of Pharmacy, Hilo, Hawaii, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Glod</surname>
                    <given-names>John W</given-names>
                  </name>
                  <role>Academic Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>National Cancer Institute, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors of this manuscript have the following competing interests: E.W.G. is a paid employee of Cancer Prevention Pharmaceuticals (CPP). He has an ownership interest in, and serves on the board of, CPP. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</p>
                </fn>
                <fn fn-type="con" id="contrib001">
                  <p>Conceived and designed the experiments: GS ASB GB EWG DE TA. Performed the experiments: GS EWG MK KH SM DE AV WF WR RW J. Kraveka J. Kaplan DM NP KN LS JB TH. Analyzed the data: GS ASB GB EWG MK RBM TA TH. Contributed reagents/materials/analysis tools: TA WF WR RW J. Kraveka J. Kaplan DM NP KN LS JB. Wrote the paper: GS ASB GB EWG DE AV WF WR RW J. Kraveka J. Kaplan DM NP KN LS MK SM KH JB TH.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>giselle.sholler@helendevoschildrens.org</email> (GS) or <email>andre.bachmann@hc.msu.edu</email> (AB)</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>27</day>
                <month>5</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2015</year>
              </pub-date>
              <volume>10</volume>
              <issue>5</issue>
              <elocation-id>e0127246</elocation-id>
              <history>
                <date date-type="received">
                  <day>29</day>
                  <month>10</month>
                  <year>2014</year>
                </date>
                <date date-type="accepted">
                  <day>11</day>
                  <month>4</month>
                  <year>2015</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2015 Saulnier Sholler et al</copyright-statement>
                <copyright-year>2015</copyright-year>
                <copyright-holder>Saulnier Sholler et al</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0127246.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>Neuroblastoma (NB) is the most common cancer in infancy and most frequent cause of death from extracranial solid tumors in children. Ornithine decarboxylase (ODC) expression is an independent indicator of poor prognosis in NB patients. This study investigated safety, response, pharmacokinetics, genetic and metabolic factors associated with ODC in a clinical trial of the ODC inhibitor difluoromethylornithine (DFMO) ± etoposide for patients with relapsed or refractory NB.</p>
                </sec>
                <sec id="sec002">
                  <title>Methods and Findings</title>
                  <p>Twenty-one patients participated in a phase I study of daily oral DFMO alone for three weeks, followed by additional three-week cycles of DFMO plus daily oral etoposide. No dose limiting toxicities (DLTs) were identified in patients taking doses of DFMO between 500-1500 mg/m2 orally twice a day. DFMO pharmacokinetics, single nucleotide polymorphisms (SNPs) in the ODC gene and urinary levels of substrates for the tissue polyamine exporter were measured. Urinary polyamine levels varied among patients at baseline. Patients with the minor T-allele at rs2302616 of the ODC gene had higher baseline levels (p=0.02) of, and larger decreases in, total urinary polyamines during the first cycle of DFMO therapy (p=0.003) and had median progression free survival (PFS) that was over three times longer, compared to patients with the major G allele at this locus although this last result was not statistically significant (p=0.07). Six of 18 evaluable patients were progression free during the trial period with three patients continuing progression free at 663, 1559 and 1573 days after initiating treatment. Median progression-free survival was less among patients having increased urinary polyamines, especially diacetylspermine, although this result was not statistically significant (p=0.056).</p>
                </sec>
                <sec id="sec003">
                  <title>Conclusions</title>
                  <p>DFMO doses of 500-1500mg/m2/day are safe and well tolerated in children with relapsed NB. Children with the minor T allele at rs2302616 of the ODC gene with relapsed or refractory NB had higher levels of urinary polyamine markers and responded better to therapy containing DFMO, compared to those with the major G allele at this locus. These findings suggest that this patient subset may display dependence on polyamines and be uniquely susceptible to therapies targeting this pathway.</p>
                </sec>
                <sec id="sec004">
                  <title>Trial Registration</title>
                  <p>Clinicaltrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01059071">NCT#01059071</ext-link>
</p>
                </sec>
              </abstract>
              <funding-group>
                <funding-statement>The Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) supported this work in collaboration with Cancer Prevention Pharmaceuticals. This trial was funded by the Beat NB Foundation, Max’s Ring of Fire, Meryl and Charles Witmer Foundation, Owen Moscone Foundation and many other donations from the families of children with neuroblastoma. PD measurements were supported in part by NIH grants CA095060 (EWG PI) and CA123065 (EWG PI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="5"/>
                <table-count count="6"/>
                <page-count count="20"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the paper and its Supporting Information files.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec005">
              <title>Introduction</title>
              <p>Neuroblastoma (NB) is a deadly childhood cancer that arises from neural crest cells of the sympathetic nervous system. The average age at diagnosis is 17 months and 50–60% of patients present with metastatic disease. NB is a heterogeneous disease, with varied risk groups [<xref rid="pone.0127246.ref001" ref-type="bibr">1</xref>]. Up to 45% of patients are in a high-risk category that includes patients with MYCN amplification or other adverse clinicopathologic features. Despite advances in treatments that include chemotherapy, surgery, radiation, high dose chemotherapy with stem cell rescue, antibody and biologic-based therapy, the overall long-term survival of patients with high risk disease remains poor at approximately 50%. Approximately 20% of patients in this high-risk group fail to respond adequately to chemotherapy and develop progressive or refractory disease. Those which complete upfront therapy will have a &gt;35% risk of relapse [<xref rid="pone.0127246.ref002" ref-type="bibr">2</xref>–<xref rid="pone.0127246.ref004" ref-type="bibr">4</xref>]. As such new therapies for patients with relapsed or refractory NB are sorely needed.</p>
              <p>In 2004, we began investigating Difluoromethylornithine (DFMO) for the treatment of high-risk NB [<xref rid="pone.0127246.ref005" ref-type="bibr">5</xref>]. DFMO is an enzyme-activated inhibitor of ornithine decarboxylase (ODC) and ODC is a rate-limiting enzyme of polyamine biosynthesis. Our preclinical studies with DFMO showed that polyamine depletion is an effective therapeutic strategy in NB [<xref rid="pone.0127246.ref006" ref-type="bibr">6</xref>]. We found that DFMO alters the polyamine-regulated p27Kip1/Rb signaling pathway that leads to G1 cell cycle arrest and prevents NB migration/invasion of cells [<xref rid="pone.0127246.ref006" ref-type="bibr">6</xref>–<xref rid="pone.0127246.ref008" ref-type="bibr">8</xref>]. We and other groups independently validated the epidemiological and laboratory evidence that indicated that ornithine decarboxylase (ODC) and several other genes in the polyamine pathway were transcriptional targets of MYCN [<xref rid="pone.0127246.ref009" ref-type="bibr">9</xref>–<xref rid="pone.0127246.ref011" ref-type="bibr">11</xref>]. Our observations with DFMO were confirmed in vivo by two groups using the TH-MYCN transgenic NB mouse model [<xref rid="pone.0127246.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0127246.ref010" ref-type="bibr">10</xref>]. We further demonstrated that ODC expression is a negative risk factor for NB independent of MYCN amplification [<xref rid="pone.0127246.ref011" ref-type="bibr">11</xref>]. ODC gene expression is directly activated by MYCN, and in a subset of patients is co-amplified with MYCN [<xref rid="pone.0127246.ref009" ref-type="bibr">9</xref>], suggests that MYCN gene amplification leads to high ODC expression and subsequent high polyamine levels which contribute to the malignant phenotype and the maintenance of NB tumorigenesis [<xref rid="pone.0127246.ref012" ref-type="bibr">12</xref>–<xref rid="pone.0127246.ref018" ref-type="bibr">18</xref>].</p>
              <p>Single nucleotide polymorphisms (SNPs) in the ODC gene have been associated with risk of specific cancers [<xref rid="pone.0127246.ref019" ref-type="bibr">19</xref>–<xref rid="pone.0127246.ref021" ref-type="bibr">21</xref>]. The minor A allele at rs2302615 in the ODC gene was found to be a risk allele for survival in patients with prior colorectal cancer [<xref rid="pone.0127246.ref022" ref-type="bibr">22</xref>], but a protective allele in patients with NB [<xref rid="pone.0127246.ref023" ref-type="bibr">23</xref>]. The SNP at rs2302615 affects binding to the surrounding DNA elements of e-box transcription factors [<xref rid="pone.0127246.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0127246.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0127246.ref023" ref-type="bibr">23</xref>], which have been found to interact with transcription factors acting at an upstream SNP (rs2302616) [<xref rid="pone.0127246.ref024" ref-type="bibr">24</xref>]. The minor T allele at rs2302616 disrupts a G-quadraplex structure in the ODC gene, increases ODC promoter activity and is associated with increased putrescine content in rectal tissues from patients with risk of colorectal cancer [<xref rid="pone.0127246.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0127246.ref025" ref-type="bibr">25</xref>]. Patients in a colorectal adenoma prevention trial with this genotype also display maximal response to a combination of agents targeting the polyamine pathway [<xref rid="pone.0127246.ref025" ref-type="bibr">25</xref>], suggesting that the minor T-allele at rs2302616 may convey a “polyamine addiction” phenotype.</p>
              <p>While the importance of ODC and polyamines in tumor growth has been well established [<xref rid="pone.0127246.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0127246.ref027" ref-type="bibr">27</xref>], the usefulness of DFMO in the treatment of pediatric NB had not been considered until recently [<xref rid="pone.0127246.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0127246.ref006" ref-type="bibr">6</xref>] and this is the first trial to evaluate DFMO clinically in NB patients. Orally administered DFMO is an experimental therapy that has never received regulatory approval for any indication. High-dose Intravenous (IV) DFMO received regulatory approvals in 1990 for first-line treatment of West African sleeping sickness (trypanosomiasis), and is used by the World Health Organization in combination with nifurtimox, also referred to as Nifurtimox-Eflornithine-Combination-Therapy (NECT) [<xref rid="pone.0127246.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0127246.ref029" ref-type="bibr">29</xref>]. Topical DFMO is the active component of a commercial therapy for hirsutism (excess facial hair) [<xref rid="pone.0127246.ref030" ref-type="bibr">30</xref>].</p>
              <p>The primary aim of this phase I clinical trial was to study the safety of the ODC inhibitor difluoromethylornithine (DFMO) alone and in combination with a cytotoxic chemotherapeutic drug in pediatric patients with refractory or recurrent NB. Etoposide was chosen for the combination, as it has reported efficacy in this patient group [<xref rid="pone.0127246.ref031" ref-type="bibr">31</xref>] and is synergistic with DFMO in some cell models [<xref rid="pone.0127246.ref032" ref-type="bibr">32</xref>]. The secondary aims were to investigate the activity, pharmacokinetics and genetic and metabolic factors associated with ODC.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec006">
              <title>Patients and Methods</title>
              <p>The protocol for this trial and supporting TREND checklist are available as supporting information; see <xref rid="pone.0127246.s003" ref-type="supplementary-material">S1 TREND Checklist</xref> and <xref rid="pone.0127246.s001" ref-type="supplementary-material">S1 Protocol</xref>.</p>
              <sec id="sec007">
                <title>Patient Eligibility</title>
                <p>The supporting TREND checklist for this trial is available as supporting information; see <xref rid="pone.0127246.s003" ref-type="supplementary-material">S1 TREND Checklist</xref>. Patients were enrolled onto the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) 002 study from March 2010 to October 2012. To be eligible for this study, subjects had to fulfill the following criteria: (a) age 0–21 years at the time of diagnosis; (b) histologic verification at either the time of original diagnosis or relapse of NB; (c) disease status verified as refractory or relapsed NB; (d) measurable disease based on measurable tumor (&gt;10 mm by CT or MRI), positive MIBG and abnormal urinary catecholamine levels or positive bone marrow biopsy/aspirate; (e) disease state was one for which there was no known curative therapy; (f) negative urine pregnancy test for female subjects of child bearing potential (onset of menses or ≥ 13 years of age); (g) adequate liver function as defined by AST and ALT &lt;10x normal. Exclusion criteria were life expectancy &lt;2 months, Lansky score &lt;30%, or subjects who were concurrently receiving another investigational drug or anticancer agent. Subjects had to be fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects). Subjects were excluded if they had an uncontrolled infection until the infection was controlled. Subjects who were not able to comply with the safety monitoring requirements of the study were also excluded. This trial was approved by the Western Institutional Review Board as well as by local Institutional Review Boards at each enrolling site as follows; University of Vermont Committees on Human Research, The Spectrum Health Institutional Review Board, M. D. Anderson-Orlando Institutional Review Board, The Institutional Review Board of Carolinas HealthCare System, and Children’s Hospital of Orange County Institutional Review Board. Written informed consent was obtained from the patients' parent(s) or guardian(s), and patients provided written assent when appropriate, prior to study entry. ClinicalTrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01059071">NCT01059071</ext-link>.</p>
              </sec>
              <sec id="sec008">
                <title>Patient Characteristics</title>
                <p>Twenty-one subjects with refractory or recurrent NB were enrolled in this study between March 2010 and October 2012. The subject characteristics are shown in <xref rid="pone.0127246.t001" ref-type="table">Table 1</xref>. Every subject had previously received standard therapy for their disease and had relapsed or was refractory to therapy. The median age was 9 years old, with a range of 1–17 years old. Additional enrollment characteristics including number and type of previous relapse treatments, MYCN status, and disease status at study entry can be found in <xref rid="pone.0127246.s002" ref-type="supplementary-material">S1 Table</xref>.</p>
                <table-wrap id="pone.0127246.t001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0127246.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Characteristics of patients enrolled in NMTRC 002.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0127246.t001g" xlink:href="pone.0127246.t001"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Enrollment</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">N</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Total Enrolled</td>
                          <td align="left" rowspan="1" colspan="1">21</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Total Received Drug</td>
                          <td align="left" rowspan="1" colspan="1">21</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Evaluable</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">N (%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Efficacy Evaluable</td>
                          <td align="left" rowspan="1" colspan="1">18 (86)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Safety Evaluable</td>
                          <td align="left" rowspan="1" colspan="1">21 (100)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Age</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">Years</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Mean</td>
                          <td align="left" rowspan="1" colspan="1">8.75</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Median</td>
                          <td align="left" rowspan="1" colspan="1">9</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Sex</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">N (%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Male</td>
                          <td align="left" rowspan="1" colspan="1">14 (67)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Female</td>
                          <td align="left" rowspan="1" colspan="1">7 (33)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Race</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">N (%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Caucasian</td>
                          <td align="left" rowspan="1" colspan="1">14 (67)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Hispanic</td>
                          <td align="left" rowspan="1" colspan="1">3 (14)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Black or African American</td>
                          <td align="left" rowspan="1" colspan="1">2 (9.5)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> More than one race or unknown</td>
                          <td align="left" rowspan="1" colspan="1">2 (9.5)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
              </sec>
              <sec id="sec009">
                <title>Study Design and Treatment</title>
                <p>The NMTRC 002 CONSORT flow diagram which has been modified for a non-randomized trial is shown (<xref rid="pone.0127246.g001" ref-type="fig">Fig 1</xref>) along with the study design flowchart (<xref rid="pone.0127246.g002" ref-type="fig">Fig 2</xref>). This trial was a standard 3+3 Phase I dose escalation design. In order to address the safety issue, patient replacement was allowed if a patient withdrew from the trial for non-drug related reasons prior to completion of 2 cycles of the protocol. Patients displaying a clinical response were allowed to remain on treatment until disease progression occurred or mutual decision of their physician and parents. Subjects were enrolled at one of four escalating doses.</p>
                <fig id="pone.0127246.g001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0127246.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>NMTRC002 CONSORT Flow Diagram- modified for non-randomized trial design.</title>
                  </caption>
                  <graphic xlink:href="pone.0127246.g001"/>
                </fig>
                <fig id="pone.0127246.g002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0127246.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Flowchart of NMTRC 002—Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide.</title>
                  </caption>
                  <graphic xlink:href="pone.0127246.g002"/>
                </fig>
                <p>Dose limiting toxicities (DLT) for single agent DFMO were evaluated in Cycles 1 (DFMO alone) and Cycle 2 (DFMO and etoposide combination) for determination of the maximum tolerated dose (MTD) of this treatment. DLT was defined as patients experiencing any toxicity specified as Grade 4 neutropenia or thrombocytopenia that persists for 7 days or longer off study drug, Grade 3 elevation of transaminases that persists for 7 days or longer off study drug, or any other Grade 3 non-hematologic toxicity, excluding alopecia or inadequately treated nausea, vomiting, diarrhea. The MTD was defined as the dose level below which DLTs are seen in ≥ two of six subjects dosed.</p>
                <p>Given the tolerability of DFMO in adult studies it is possible that these endpoints, DLT and MTD, may not be met at these doses chosen. These doses will be evaluated for biologic activity through measurement of urinary polyamines to determine if higher dosing is required in future studies.</p>
              </sec>
              <sec id="sec010">
                <title>Drug Formulation and Administration</title>
                <p>Subjects received single agent DFMO administered orally on Days 1–21 of the first 21-day cycle. DFMO was supplied as a powder that was dissolved in juice or water prior to administration. The starting dose was 500 mg/m<sup>2</sup> PO BID (Dose Level 1). Dose escalation took place in a standard 3+3 design, in which doses increased by approximately 20 to 25% in successive 3-subject cohorts. These additional doses included Dose Level 2 at 750 mg/m2 PO BID, Dose Level 3 at 1000 mg/m2 PO BID, and Dose Level 4 at 1500 mg/m2 PO BID. Enrollment of the next cohort occurred after the entire previous cohort had completed both cycles 1 (single agent) and 2 (combination) of treatment without any dose limiting toxicity (DLT), as reviewed by the Data and Safety Monitoring Committee. After the first cycle of single agent DFMO all patients received DFMO in combination with etoposide in cycles 2–5. During these cycles, subjects continued to receive DFMO at the dose received during cycle 1 in addition to oral Etoposide at 50 mg/m<sup>2</sup>/dose (rounded to the nearest 50 mg) once daily for the first 14 days of Cycles 2–5. The final cohort of DFMO received an additional 3 enrollments as a confirmation cohort, so that six subjects received a maximum of 1500 mg/m<sup>2</sup> BID dose of DFMO.</p>
                <p>The etoposide was discontinued in some patients after cycle 5 due to the concern for risk of secondary leukemia. The decision was made by the site physician/primary investigator and patient family.</p>
              </sec>
              <sec id="sec011">
                <title>Patient safety and treatment response evaluation</title>
                <p>Weekly monitoring for treatment related toxicities included a physical exam, vital signs (temperature, pulse rate, and sitting blood pressure) CBC, AST/ALT, LDH, bilirubin, electrolytes, BUN, creatinine, review and recording of concomitant medications, and monitoring of AE’s with a review of concurrent illnesses. In addition, Lansky or ECOG score and urine catecholamines were measured prior to every 21 day cycle. An audiogram was performed at the end of cycles 1, 3, and 5. Subjects without bone marrow metastases were required to have adequate bone marrow function as defined by ANC &gt; 500/μl and platelets &gt; 50,000/μl before starting chemotherapy. Clinical and laboratory adverse events were graded according to the NCI-common terminology criteria for adverse events (CTCAE) version 3.0.</p>
                <p>Tumor and clinical responses were monitored as secondary endpoints. Eighteen subjects were evaluated for efficacy. This study used the (RECIST) Response Evaluation Criteria measurements in Solid Tumor from the NCI modified for pediatrics as well as MIBG or PET and bone marrow response. Tumor assessments/imaging studies were obtained at baseline &gt;7 days from prior therapy and &lt; 21 days from the start of study therapy. These were repeated at the end of the first cycle and again after every other cycle.</p>
              </sec>
              <sec id="sec012">
                <title>Pharmacokinetic (PK) Analytical Method and Sample Collection</title>
                <p>Patients were consented for all pharmacokinetic sampling and analysis. DFMO analytical methods were performed in compliance with Good Laboratory Practice (GLP), under contract with inVentiv Health Clinique (Quebec, Canada). Briefly, the analyte DFMO and its internal standard were extracted from a 0.025 mL aliquot of human serum. The extracted samples were injected into a liquid chromatograph equipped with an Atlantis Hilic Silica, 50 x 4.6 mm, 3 μm column. The mobile phase A was a mixture of Milli-Q type water with acetonitrile and ammonium acetate. The validated calibration range for this assay was from 50 to 100000 ng/mL. Blood was drawn from patients immediately prior to taking a morning oral DFMO dose during cycles 1 (DFMO alone) and 2 (DFMO + etoposide) and at 0.5, 1, 3 and 6 hours after drug administration. DFMO levels were then assessed in serum obtained from these blood samples. Blood was not collected beyond 6 hours post dose as this trial was conducted on an outpatient basis, and this was judged to be an undue burden on patients.</p>
              </sec>
              <sec id="sec013">
                <title>ODC Genotype</title>
                <p>Patients were consented for genetic analysis in NMTRC 002. ODC rs2302615 and rs2302616 genotypes were determined from blood samples by pyrosequencing methods, under contract with EpigenDx (epigendx.com).</p>
              </sec>
              <sec id="sec014">
                <title>Urinary Polyamine Levels</title>
                <p>Patients were consented for urine analysis in NMTRC 002. Spot urine (first void of the day) was collected on days 1, 8, and 15 of cycle 1 (DFMO only) and frozen at -80°C until analysis of polyamines levels. Polyamines with at least one free primary amine were quantified using reverse-phase high-performance liquid chromatography (HPLC) as previously described [<xref rid="pone.0127246.ref033" ref-type="bibr">33</xref>]. Urinary N<sup>1</sup>,N<sup>12</sup>-diacetylspermine (N<sup>1</sup>,N<sup>12</sup>-Ac<sub>2</sub>Spm or DAS) was determined using the auto DAS reagent kit (Alfresa Pharma Co., Osaka, Japan), according to the manufacturer's instructions. The assay involves the specific binding between a bovine serum albumin-acetylspermine conjugate, as a DAS mimic, and colloidal gold antibody complexes, and has been previously described [<xref rid="pone.0127246.ref034" ref-type="bibr">34</xref>].</p>
              </sec>
              <sec id="sec015">
                <title>Statistical Methods</title>
                <p>Pharmacokinetic parameters C<sub>max</sub>, t<sub>max</sub> and AUC<sub>0–6</sub> are presented as the mean and standard deviation of all observed values at each dose level, and were analyzed using SAS (ver. 9.2). Urinary polyamine levels were derived from duplicate measurements of individual samples. Friedman's test for repeated measures analysis of variance was used to assess changes in contents of individual urinary polyamines.</p>
                <p>Analyses of associations among PFS, urinary polyamines, and genotype were based on nonparametric methods. These analyses include point estimation, interval estimation, and hypothesis tests. Median progression-free survival was estimated using the Kaplan-Meier method [<xref rid="pone.0127246.ref035" ref-type="bibr">35</xref>]; 95% confidence intervals were estimated based on the cumulative hazard (method <italic>survfit</italic> from the R <italic>survival</italic> [<xref rid="pone.0127246.ref036" ref-type="bibr">36</xref>–<xref rid="pone.0127246.ref038" ref-type="bibr">38</xref>] package). Two-sample progression-free survival difference tests were based on log-rank test [<xref rid="pone.0127246.ref039" ref-type="bibr">39</xref>] (method <italic>survdiff</italic> from the <italic>survival</italic> package). Confidence intervals on the means of polyamine measurements were obtained by bootstrapping [<xref rid="pone.0127246.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0127246.ref041" ref-type="bibr">41</xref>]. Hypothesis tests on differences of polyamine concentrations were based on the Wilcoxon rank-sum test (method <italic>wilcox</italic>.<italic>test</italic> of the R <italic>stats</italic> [<xref rid="pone.0127246.ref036" ref-type="bibr">36</xref>] package).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec016">
              <title>Results</title>
              <sec id="sec017">
                <title>Patient Enrollment</title>
                <p>Three evaluable subjects were enrolled at 500 mg/m2 BID, three evaluable subjects at 750 mg/m2 BID, three evaluable subjects at 1000 mg/m2 BID, and six subjects at 1500 mg/m2 BID. Twenty-one subjects received at least one dose of DFMO as a single agent and were evaluable for safety. Eighteen of those subjects completed cycle 1 and were evaluable for efficacy of DFMO alone. After one cycle of DFMO alone, patients were able to continue the study with DFMO and etoposide combination therapy. Of the initial eighteen patients, fifteen subjects completed at least one additional cycle of DFMO with etoposide and comprise the population evaluable for dose limiting toxicity. Of the eighteen subjects that were evaluable for efficacy, 2 subjects completed 1 cycle, 7 subjects completed 3 cycles, 2 subjects completed 5 cycles, 1 subject completed 7 cycles (cycles 6–7 DFMO alone), 1 subject completed 10 cycles, 1 subject completed 12 cycles (cycles 7–12 DFMO alone), 1 subject completed 15 cycles (cycles 6–15 DFMO alone), 2 subjects completed 17 cycles (on subject cycles 6–17 DFMO alone), and 1 subject completed 43 cycles on study (cycles 7–43 DFMO alone).</p>
              </sec>
              <sec id="sec018">
                <title>Safety of Oral DFMO and Etoposide</title>
                <p>No dose-limiting toxicities (DLTs) or drug related serious adverse events (SAEs) were observed in this study. Study related (possibly, probably and definitely related) toxicities observed during all cycles are summarized in <xref rid="pone.0127246.t002" ref-type="table">Table 2</xref>. Those related to DFMO alone consisted of anemia (n = 3), ANC decrease (n = 2), decreased platelet count (n = 2), ALT increase (n = 1), AST increase (n = 1), anorexia (n = 1), constipation (n = 1), diarrhea (n = 1), infection (conjunctivitis) (n = 1), hypoalbuminemia (n = 1), hypophosphatemia (n = 1), increased GGT (n = 1), sleep disturbance (n = 1), urinary retention (n = 1) and vomiting (n = 1). Six subjects were enrolled in the 1500 mg/m<sup>2</sup> BID dose and no DLTs were observed. Thus, the dose of DFMO recommended for Phase II evaluation is 1500 mg/m<sup>2</sup> BID. A maximum tolerated dose (MTD) was not established in this study.</p>
                <table-wrap id="pone.0127246.t002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0127246.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Study Safety Data: Toxicity of Oral DFMO and Etoposide.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0127246.t002g" xlink:href="pone.0127246.t002"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th colspan="4" align="center" rowspan="1">Maximum grade of toxic effects, Cycle 1</th>
                          <th colspan="4" align="center" rowspan="1">Maximum grade of toxic effects, Cycle 2–43</th>
                        </tr>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1">n = 21</th>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1">n = 17</th>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1">Grade 2</th>
                          <th align="left" rowspan="1" colspan="1">Grade 3</th>
                          <th align="left" rowspan="1" colspan="1">Grade 4</th>
                          <th align="left" rowspan="1" colspan="1">Grade 5</th>
                          <th align="left" rowspan="1" colspan="1">Grade 2</th>
                          <th align="left" rowspan="1" colspan="1">Grade 3</th>
                          <th align="left" rowspan="1" colspan="1">Grade 4</th>
                          <th align="left" rowspan="1" colspan="1">Grade 5</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Hematologic Toxic Effects</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Anemia</td>
                          <td align="left" rowspan="1" colspan="1">2 (10%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">4 (24%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Neutrophil count decrease</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">3 (18%)</td>
                          <td align="left" rowspan="1" colspan="1">2 (12%)</td>
                          <td align="left" rowspan="1" colspan="1">2 (12%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Platelet count decrease</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">White blood cell decreased</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Non-hematologic Toxic Effects</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">ALT elevation</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Anorexia</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">AST elevation</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Conjunctivitis</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Constipation</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Diarrhea</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">GGT elevation</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Hypoalbuminemia</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Hypophosphatemia</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Infection, sinus</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Mouth pain</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Nausea</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Neuropathy</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Pain</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Rash</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">1 (6%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Sleep disturbance</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Urinary retention</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Vomiting</td>
                          <td align="left" rowspan="1" colspan="1">1 (5%)</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                          <td align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t002fn001">
                      <p>Percentages are calculated as number of patients with an event divided by number of patients in group that received drug.</p>
                    </fn>
                    <fn id="t002fn002">
                      <p>ALT = alanine aminotransferase</p>
                    </fn>
                    <fn id="t002fn003">
                      <p>AST = aspartate aminotransferase</p>
                    </fn>
                    <fn id="t002fn004">
                      <p>GGT = gamma-glutamyl transpeptidase</p>
                    </fn>
                    <fn id="t002fn005">
                      <p>Adverse events attributed (possibly, probably, or definitely) to DFMO (cycle 1) or DFMO/etoposide (cycles 2–43) across all dose levels</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec019">
                <title>Pharmacokinetics of DFMO in children with NB</title>
                <p>DFMO serum measurements were performed in all 21 patients. Samples were collected from patients prior to, and again at times 0.5, 1, 3 and 6 hours following drug administration on days 1 and 8 of the first cycle. DFMO serum samples were also collected from selected patients in the higher dose groups (750, 1000, 1500 mg/m<sup>2</sup>) during cycle 2. The serum DFMO concentrations (mean and sd) in all patients receiving 750 mg/m<sup>2</sup> (mean ± standard deviation) is shown in <xref rid="pone.0127246.g003" ref-type="fig">Fig 3</xref>. DFMO doses were administered orally twice daily over a 21 day cycle. Subsequent cycles commenced the day following the last day of the previous cycle. Maximum DFMO concentrations, relative to dose, are reported in <xref rid="pone.0127246.t003" ref-type="table">Table 3</xref>. Overall average serum DFMO concentrations ranged from 9.54 μg/ml (52.24 μM) in patients receiving 500 mg/m<sup>2</sup> to 30.71 μg/ml (168.10 μM) in patients receiving 1500 mg/m<sup>2</sup>. The mean t<sub>max</sub> occurred between 2.50 and 3.75 hours, in all dose groups. The mean AUC<sub>0–6 h</sub> ranged from 39 hr-μg/ml at 500 mg/m<sup>2</sup>, to 121 hr-μg/ml in the 1500 mg/m<sup>2</sup> dose group. The highest single serum concentration measured was 78.53 g/ml during cycle 1 in one patient in the highest dose group. This subject’s serum levels were otherwise unremarkable when compared with the other subjects in this dose group. As seen in <xref rid="pone.0127246.g003" ref-type="fig">Fig 3</xref> and <xref rid="pone.0127246.t003" ref-type="table">Table 3</xref>, there was significant variation in DFMO PK parameters among patients, possibly related to differences in dose administration time relative to sampling times, and the overall duration of sampling relative to the elimination half-life of DFMO, which is 2–4 hours (50) in adults. However, mean Cmax and AUC clearly increased in a linear fashion, in proportion to the oral doses administered, and mean tmax was consistent across dose groups.</p>
                <fig id="pone.0127246.g003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0127246.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>Serum DFMO concentration versus time measurements for three patients receiving 750 mg/m<sup>2</sup> PO BID during cycle 1 of therapy.</title>
                  </caption>
                  <graphic xlink:href="pone.0127246.g003"/>
                </fig>
                <table-wrap id="pone.0127246.t003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0127246.t003</object-id>
                  <label>Table 3</label>
                  <caption>
                    <title>DFMO Pharmacokinetic Parameters (mean ± SD) by Dose Level.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0127246.t003g" xlink:href="pone.0127246.t003"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">PO BID Dose (mg/m<sup>2</sup>)</th>
                          <th align="left" rowspan="1" colspan="1">Cycle</th>
                          <th align="left" rowspan="1" colspan="1">C<sub>max</sub> (mcg/ml) mean±SD</th>
                          <th align="left" rowspan="1" colspan="1">t<sub>max</sub> hours</th>
                          <th align="left" rowspan="1" colspan="1">AUC<sub>0–6 hrs</sub> (mcg/ml)●hrs</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">500</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">9.54 ± 5.36</td>
                          <td align="left" rowspan="1" colspan="1">3.75 ± 1.39</td>
                          <td align="left" rowspan="1" colspan="1">39.90 ± 24.16</td>
                        </tr>
                        <tr>
                          <td rowspan="2" align="left" colspan="1">750</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">11.93 ± 5.22</td>
                          <td align="left" rowspan="1" colspan="1">3.60 ± 1.26</td>
                          <td align="left" rowspan="1" colspan="1">47.36 ± 18.57</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">14.23 ± 7.92</td>
                          <td align="left" rowspan="1" colspan="1">2.60 ± 0.89</td>
                          <td align="left" rowspan="1" colspan="1">62.84 ± 39.47</td>
                        </tr>
                        <tr>
                          <td rowspan="2" align="left" colspan="1">1000</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">14.71 ± 9.07</td>
                          <td align="left" rowspan="1" colspan="1">3.17 ± 1.60</td>
                          <td align="left" rowspan="1" colspan="1">60.05 ± 34.53</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">14.33 ± 6.18</td>
                          <td align="left" rowspan="1" colspan="1">3.00 ± 0.00</td>
                          <td align="left" rowspan="1" colspan="1">50.18 ± 32.57</td>
                        </tr>
                        <tr>
                          <td rowspan="2" align="left" colspan="1">1500</td>
                          <td align="left" rowspan="1" colspan="1">1</td>
                          <td align="left" rowspan="1" colspan="1">28.89±14.96</td>
                          <td align="left" rowspan="1" colspan="1">2.88 ± 1.45</td>
                          <td align="left" rowspan="1" colspan="1">108.38 ± 53.23</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2</td>
                          <td align="left" rowspan="1" colspan="1">30.71 ± 8.18</td>
                          <td align="left" rowspan="1" colspan="1">2.50 ±0.90</td>
                          <td align="left" rowspan="1" colspan="1">120.69 ± 31.22</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
                <sec id="sec020">
                  <title>Rationale for genetic and metabolic markers of polyamine metabolism and pharmacodynamics (PD) measures of DFMO effect</title>
                  <p><xref rid="pone.0127246.g004" ref-type="fig">Fig 4</xref> depicts the polyamine metabolic pathway and highlights the relationship between ODC genotypes (rs2302615 and rs2302616), affecting ODC expression, and their relationship to urinary polyamines. The figure shows the substrate relationships for the diamine and acetylpolyamine exporter [<xref rid="pone.0127246.ref042" ref-type="bibr">42</xref>–<xref rid="pone.0127246.ref044" ref-type="bibr">44</xref>], which include putrescine, monoacetylspermidine and diacetylspermine (DAS) but not spermidine or spermine. Levels of these exported amines might be expected to reflect changes in tissue ODC expression, as polyamine export is known as one component of polyamine homeostatic regulation [<xref rid="pone.0127246.ref045" ref-type="bibr">45</xref>].</p>
                  <fig id="pone.0127246.g004" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0127246.g004</object-id>
                    <label>Fig 4</label>
                    <caption>
                      <title>Rationale for DFMO- and specific genetic and metabolic markers of DFMO effect, in neuroblastoma</title>
                      <p>. ODC transcription is influenced by specific genetic variability, including the SNPs rs2302615 [<xref rid="pone.0127246.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0127246.ref022" ref-type="bibr">22</xref>] and rs2302616 [<xref rid="pone.0127246.ref024" ref-type="bibr">24</xref>]. The DFMO target ODC decarboxylates ornithine to form the diamine putrescine, which is then metabolized into longer chain amines. Spermidine is a substrate for two acetyltransferases that monoacetylate this amine at either the N<sup><bold>1</bold></sup> or N<sup><bold>8</bold></sup> positions. Spermine is a substrate for one of these transferases (SAT1), which diacetylates this amine. Putrescine, the monoacetylspermidines and diacetylspermine are all substrates for the solute carrier transporter SLC3A2/Y+LAT, which exports these amines.</p>
                    </caption>
                    <graphic xlink:href="pone.0127246.g004"/>
                  </fig>
                  <p>First morning void spot urines from each patient were evaluated for polyamines as described in Methods. <xref rid="pone.0127246.t004" ref-type="table">Table 4</xref> shows data (means ± SD) at baseline (cycle 1, day 1) for seven metabolites in the polyamine pathway, including putrescine, spermidine, spermine and the acetylderivatives of spermidine and spermine. Listed in rank order in this table, N<sup>8</sup>AcSpd was the most prevalent amine in the urines of these patients at baseline, followed by N<sup>1</sup>AcSpd, putrescine, DAS, spermine, N<sup>1</sup>-acetylspermine (N<sup>1</sup>AcSpm) and spermidine. Values for each metabolite varied significantly, as indicated by the large standard deviation for each metabolite.</p>
                  <table-wrap id="pone.0127246.t004" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0127246.t004</object-id>
                    <label>Table 4</label>
                    <caption>
                      <title>Urinary polyamine metabolites from patients at baseline and during first two weeks of DFMO therapy.</title>
                    </caption>
                    <alternatives>
                      <graphic id="pone.0127246.t004g" xlink:href="pone.0127246.t004"/>
                      <table frame="hsides" rules="groups">
                        <colgroup span="1">
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                        </colgroup>
                        <thead>
                          <tr>
                            <th align="left" rowspan="1" colspan="1">Polyamine</th>
                            <th align="left" rowspan="1" colspan="1">C1D1 Mean (μmol/g Creatinine) (N = 19)</th>
                            <th align="left" rowspan="1" colspan="1">Standard Deviation (μmol/g Creatinine)</th>
                            <th align="left" rowspan="1" colspan="1">P-value for decrease from C1D1 to C1D8 (N = 19)<xref rid="t004fn004" ref-type="table-fn">*</xref>
</th>
                            <th align="left" rowspan="1" colspan="1">P-value for decrease from C1D1 to C1D15 (N = 16)<xref rid="t004fn004" ref-type="table-fn">*</xref>
</th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">
                              <bold>N</bold>
                              <sup>
                                <bold>8</bold>
                              </sup>
                              <bold>AcSpd</bold>
                            </td>
                            <td align="char" char="." rowspan="1" colspan="1">4.72</td>
                            <td align="char" char="." rowspan="1" colspan="1">3.18</td>
                            <td align="left" rowspan="1" colspan="1">NS<xref rid="t004fn005" ref-type="table-fn">**</xref>
</td>
                            <td align="left" rowspan="1" colspan="1">NS</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">
                              <bold>N</bold>
                              <sup>
                                <bold>1</bold>
                              </sup>
                              <bold>AcSpd</bold>
                            </td>
                            <td align="char" char="." rowspan="1" colspan="1">3.96</td>
                            <td align="char" char="." rowspan="1" colspan="1">3.18</td>
                            <td align="left" rowspan="1" colspan="1">0.018</td>
                            <td align="left" rowspan="1" colspan="1">0.005</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">
                              <bold>Putrescine</bold>
                            </td>
                            <td align="char" char="." rowspan="1" colspan="1">1.93</td>
                            <td align="char" char="." rowspan="1" colspan="1">7.02</td>
                            <td align="left" rowspan="1" colspan="1">NS</td>
                            <td align="left" rowspan="1" colspan="1">NS</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">
                              <bold>N</bold>
                              <sup>
                                <bold>1</bold>
                              </sup>
                              <bold>N</bold>
                              <sup>
                                <bold>12</bold>
                              </sup>
                              <bold>Ac</bold>
                              <sub>
                                <bold>2</bold>
                              </sub>
                              <bold>Spm</bold>
                            </td>
                            <td align="char" char="." rowspan="1" colspan="1">0.80</td>
                            <td align="char" char="." rowspan="1" colspan="1">0.62</td>
                            <td align="left" rowspan="1" colspan="1">NS</td>
                            <td align="left" rowspan="1" colspan="1">NS</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">
                              <bold>Spermine</bold>
                            </td>
                            <td align="char" char="." rowspan="1" colspan="1">0.55</td>
                            <td align="char" char="." rowspan="1" colspan="1">1.71</td>
                            <td align="left" rowspan="1" colspan="1">NS</td>
                            <td align="left" rowspan="1" colspan="1">NS</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">
                              <bold>N</bold>
                              <sup>
                                <bold>1</bold>
                              </sup>
                              <bold>AcSpm</bold>
                            </td>
                            <td align="char" char="." rowspan="1" colspan="1">0.33</td>
                            <td align="char" char="." rowspan="1" colspan="1">0.74</td>
                            <td align="left" rowspan="1" colspan="1">NS</td>
                            <td align="left" rowspan="1" colspan="1">NS</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">
                              <bold>Spermidine</bold>
                            </td>
                            <td align="char" char="." rowspan="1" colspan="1">0.26</td>
                            <td align="char" char="." rowspan="1" colspan="1">0.25</td>
                            <td align="left" rowspan="1" colspan="1">NS</td>
                            <td align="left" rowspan="1" colspan="1">NS</td>
                          </tr>
                        </tbody>
                      </table>
                    </alternatives>
                    <table-wrap-foot>
                      <fn id="t004fn001">
                        <p>C1D1 = cycle 1 day 1 (defined as baseline)</p>
                      </fn>
                      <fn id="t004fn002">
                        <p>C1D8 = cycle 1 day 8 after starting DFMO on day1</p>
                      </fn>
                      <fn id="t004fn003">
                        <p>C1D15 = cycle 1 day 15 after starting DFMO on day 1</p>
                      </fn>
                      <fn id="t004fn004">
                        <p>*Determined by Friedman two-way analysis of variance</p>
                      </fn>
                      <fn id="t004fn005">
                        <p>**Not significant</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <p>To determine if these baseline values were affected by treatment, all seven of these metabolites were evaluated for changes over the first two week period of treatment. Only N<sup>1</sup>AcSpd (N = 15 cases) showed a significant change over time (p = 0.004 unadjusted and p = 0.036 Bonferonni adjusted).</p>
                  <p>The changes in N<sup>1</sup>AcSpd were then further evaluated by paired comparisons between each of the 3 days (baseline versus day 8, baseline versus day 15, and day 8 versus day 15). The paired comparisons show that there was a significant decline from Day 1 to 8 (p = 0.018) for the N = 19 patients with Day 1 and 8 data, and a significant decline from Day 1 to 15 (p = 0.005) for N = 16 patients with Day 1 and 15 data. No change was seen between Day 8 and 15 (p = 1.000) for those N = 16 patients with complete data.</p>
                  <p>A standard repeated measures analysis of variance was used to confirm the apparent changes in N<sup>1</sup>AcSpd during the first two weeks of treatment. This parametric approach also used the 15 complete cases as did the paired comparisons analysis using the Friedman's test. The within subject results identify a significant linear effect (p = 0.003) and a marginal quadratic effect (p = 0.075). This analysis indicates that the mean values of N<sup>1</sup>AcSpd decline over time with most of the decline occurring during the first week of treatment. The bending or bottoming out at Day 8 and 15 leads to the quadratic effect. This is consistent with the paired Friedman's comparisons. As was the case with the overall Friedman's test, the overall change with the univariate repeated measures model show a significant change over time (p = 0.002).</p>
                  <p>We looked for patterns of these metabolites in relationship to ODC genotypes and the treatment period to determine if changes might be associated with either genetic factors or therapy. <xref rid="pone.0127246.t005" ref-type="table">Table 5</xref> lists individual patients rank-ordered by PFS and includes ODC genotype and urinary polyamine contents. For simplicity, in <xref rid="pone.0127246.t005" ref-type="table">Table 5</xref> we only show the sum of putrescine, N<sup>1</sup>AcSpd, N<sup>8</sup>AcSpd and DAS, which are true substrates for the tissue polyamine exporter. <xref rid="pone.0127246.t006" ref-type="table">Table 6</xref> presents results of associations of baseline and changes in urinary polyamines after one week of DFMO therapy and PFS with ODC genotypes. Median PFS was over 3 times greater in patients with any minor T allele, compared to GG, at rs2302616 (209 days compared to 62 days) with marginal statistical significance (P = 0.056). Differences in PFS by rs2302615 were not statistically significant. The variation observed in baseline urinary polyamines seemed to be at least partially explained by ODC genotype. Levels of urinary substrates for the polyamine exporter were nearly twice as high in samples from patients with the minor T-allele, compared to those with the GG genotype, at rs2302616 (P = 0.021). Urinary polyamines were higher for the GG genotype, compared to any A, at rs2302615, but this difference was not significant (P = 0.67). The effect of DFMO treatment was more pronounced as a function of ODC genotype. Urinary polyamine levels decreased by nearly 50% from baseline values after one week of DFMO therapy in patients with the minor T allele at rs2302616, while increasing nearly 25% in patients with the GG genotype at rs2302616 (P = 0.003). The effect of DFMO was also quantitatively greater in patients with the GG genotype, compared to any A allele, at rs2302615, but the difference was not statistically significant.</p>
                  <table-wrap id="pone.0127246.t005" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0127246.t005</object-id>
                    <label>Table 5</label>
                    <caption>
                      <title>Rank-ordered PFS by DFMO dose, ODC genotype and urinary polyamines.</title>
                    </caption>
                    <alternatives>
                      <graphic id="pone.0127246.t005g" xlink:href="pone.0127246.t005"/>
                      <table frame="hsides" rules="groups">
                        <colgroup span="1">
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                        </colgroup>
                        <thead>
                          <tr>
                            <th align="left" rowspan="1" colspan="1">Patient #</th>
                            <th align="left" rowspan="1" colspan="1">PFS (days)</th>
                            <th align="left" rowspan="1" colspan="1">Response after Cycle 1 (DFMO)</th>
                            <th align="left" rowspan="1" colspan="1">Best Response (CT/MIBG)</th>
                            <th align="left" rowspan="1" colspan="1">Status or Reason off study<xref rid="t005fn001" ref-type="table-fn">*</xref>
</th>
                            <th align="left" rowspan="1" colspan="1">DFMO Dose (mg/m<sup>2</sup>)</th>
                            <th align="left" rowspan="1" colspan="1">ODC SNP rs2302615/ rs2302616</th>
                            <th align="left" rowspan="1" colspan="1">UPA <xref rid="t005fn003" ref-type="table-fn">**</xref>Cycle 1 Day 1 (μmol/g Creatinine)</th>
                            <th align="left" rowspan="1" colspan="1">UPA <xref rid="t005fn003" ref-type="table-fn">**</xref>Cycle 1 Day 8 (μmol/g Creatinine)</th>
                            <th align="left" rowspan="1" colspan="1">DAS increase from Cycle 1 Day 1</th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">1</td>
                            <td align="left" rowspan="1" colspan="1">1573</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">SD/PR</td>
                            <td align="left" rowspan="1" colspan="1">Alive (PF)</td>
                            <td align="left" rowspan="1" colspan="1">500</td>
                            <td align="left" rowspan="1" colspan="1">GA/TG</td>
                            <td align="left" rowspan="1" colspan="1">NA<xref rid="t005fn004" ref-type="table-fn">***</xref>
</td>
                            <td align="left" rowspan="1" colspan="1">15.7</td>
                            <td align="left" rowspan="1" colspan="1">NA</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">2</td>
                            <td align="left" rowspan="1" colspan="1">1559</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">Alive (PF)</td>
                            <td align="left" rowspan="1" colspan="1">500</td>
                            <td align="left" rowspan="1" colspan="1">GG/TG</td>
                            <td align="left" rowspan="1" colspan="1">19.72</td>
                            <td align="left" rowspan="1" colspan="1">11.69</td>
                            <td align="left" rowspan="1" colspan="1">No</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">3</td>
                            <td align="left" rowspan="1" colspan="1">663</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">SD/PR</td>
                            <td align="left" rowspan="1" colspan="1">Alive (PF)</td>
                            <td align="left" rowspan="1" colspan="1">1500</td>
                            <td align="left" rowspan="1" colspan="1">GG/TT</td>
                            <td align="left" rowspan="1" colspan="1">9</td>
                            <td align="left" rowspan="1" colspan="1">5.61</td>
                            <td align="left" rowspan="1" colspan="1">Yes</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">4</td>
                            <td align="left" rowspan="1" colspan="1">418</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">750</td>
                            <td align="left" rowspan="1" colspan="1">GA/GG</td>
                            <td align="left" rowspan="1" colspan="1">2.25</td>
                            <td align="left" rowspan="1" colspan="1">7.8</td>
                            <td align="left" rowspan="1" colspan="1">No</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">5</td>
                            <td align="left" rowspan="1" colspan="1">239</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">1000</td>
                            <td align="left" rowspan="1" colspan="1">GG/TG</td>
                            <td align="left" rowspan="1" colspan="1">40.12</td>
                            <td align="left" rowspan="1" colspan="1">8.71</td>
                            <td align="left" rowspan="1" colspan="1">No</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">6</td>
                            <td align="left" rowspan="1" colspan="1">209</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">(CT Neg)/PR</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">1500</td>
                            <td align="left" rowspan="1" colspan="1">GA/TG</td>
                            <td align="left" rowspan="1" colspan="1">12.23</td>
                            <td align="left" rowspan="1" colspan="1">3.98</td>
                            <td align="left" rowspan="1" colspan="1">No</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">7</td>
                            <td align="left" rowspan="1" colspan="1">136</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Leukemia</td>
                            <td align="left" rowspan="1" colspan="1">1500</td>
                            <td align="left" rowspan="1" colspan="1">GG/GG</td>
                            <td align="left" rowspan="1" colspan="1">4.58</td>
                            <td align="left" rowspan="1" colspan="1">6.99</td>
                            <td align="left" rowspan="1" colspan="1">No</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">8</td>
                            <td align="left" rowspan="1" colspan="1">103</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">750</td>
                            <td align="left" rowspan="1" colspan="1">GG/GG</td>
                            <td align="left" rowspan="1" colspan="1">5.04</td>
                            <td align="left" rowspan="1" colspan="1">NA<xref rid="t005fn004" ref-type="table-fn">***</xref>
</td>
                            <td align="left" rowspan="1" colspan="1">No</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">9</td>
                            <td align="left" rowspan="1" colspan="1">94</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">500</td>
                            <td align="left" rowspan="1" colspan="1">GG/TG</td>
                            <td align="left" rowspan="1" colspan="1">10.18</td>
                            <td align="left" rowspan="1" colspan="1">4.2</td>
                            <td align="left" rowspan="1" colspan="1">Yes</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">10</td>
                            <td align="left" rowspan="1" colspan="1">67</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">750</td>
                            <td align="left" rowspan="1" colspan="1">GG/GG</td>
                            <td align="left" rowspan="1" colspan="1">26.75</td>
                            <td align="left" rowspan="1" colspan="1">22.08</td>
                            <td align="left" rowspan="1" colspan="1">Yes</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">11</td>
                            <td align="left" rowspan="1" colspan="1">64</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">1000</td>
                            <td align="left" rowspan="1" colspan="1">AA/GG</td>
                            <td align="left" rowspan="1" colspan="1">4.97</td>
                            <td align="left" rowspan="1" colspan="1">3.89</td>
                            <td align="left" rowspan="1" colspan="1">Yes</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">12</td>
                            <td align="left" rowspan="1" colspan="1">62</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">1500</td>
                            <td align="left" rowspan="1" colspan="1">AA/GG</td>
                            <td align="left" rowspan="1" colspan="1">2.85</td>
                            <td align="left" rowspan="1" colspan="1">3.77</td>
                            <td align="left" rowspan="1" colspan="1">No</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">13</td>
                            <td align="left" rowspan="1" colspan="1">62</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">1500</td>
                            <td align="left" rowspan="1" colspan="1">GA/TG</td>
                            <td align="left" rowspan="1" colspan="1">11.53</td>
                            <td align="left" rowspan="1" colspan="1">8.81</td>
                            <td align="left" rowspan="1" colspan="1">Yes</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">14</td>
                            <td align="left" rowspan="1" colspan="1">62</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">1500</td>
                            <td align="left" rowspan="1" colspan="1">GA/TG</td>
                            <td align="left" rowspan="1" colspan="1">15.35</td>
                            <td align="left" rowspan="1" colspan="1">7.38</td>
                            <td align="left" rowspan="1" colspan="1">Yes</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">15</td>
                            <td align="left" rowspan="1" colspan="1">59</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">1000</td>
                            <td align="left" rowspan="1" colspan="1">GA/GG</td>
                            <td align="left" rowspan="1" colspan="1">6.8</td>
                            <td align="left" rowspan="1" colspan="1">3.28</td>
                            <td align="left" rowspan="1" colspan="1">Yes</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">16</td>
                            <td align="left" rowspan="1" colspan="1">57</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">SD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">750</td>
                            <td align="left" rowspan="1" colspan="1">GG/GG</td>
                            <td align="left" rowspan="1" colspan="1">2.16</td>
                            <td align="left" rowspan="1" colspan="1">1.94</td>
                            <td align="left" rowspan="1" colspan="1">Yes</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">17</td>
                            <td align="left" rowspan="1" colspan="1">31</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">750</td>
                            <td align="left" rowspan="1" colspan="1">GA/GG</td>
                            <td align="left" rowspan="1" colspan="1">15.34</td>
                            <td align="left" rowspan="1" colspan="1">13.46</td>
                            <td align="left" rowspan="1" colspan="1">Yes</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">18</td>
                            <td align="left" rowspan="1" colspan="1">21</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">PD</td>
                            <td align="left" rowspan="1" colspan="1">1500</td>
                            <td align="left" rowspan="1" colspan="1">GG/TG</td>
                            <td align="left" rowspan="1" colspan="1">7.49</td>
                            <td align="left" rowspan="1" colspan="1">5.93</td>
                            <td align="left" rowspan="1" colspan="1">Yes</td>
                          </tr>
                        </tbody>
                      </table>
                    </alternatives>
                    <table-wrap-foot>
                      <fn id="t005fn001">
                        <p>*PF = progression free, PD = progressive disease</p>
                      </fn>
                      <fn id="t005fn002">
                        <p>2<sup>nd</sup> Leukemia = secondary leukemia</p>
                      </fn>
                      <fn id="t005fn003">
                        <p>**Substrates for the tissue polyamine exporter SLC3A2 include the sum of putrescine, N1AcSpd, N8AcSpd and DAS; D1C1 = day 1, cycle 1, D8C1 = day 8 cycle 1</p>
                      </fn>
                      <fn id="t005fn004">
                        <p>***NA = samples not available</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <table-wrap id="pone.0127246.t006" orientation="portrait" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pone.0127246.t006</object-id>
                    <label>Table 6</label>
                    <caption>
                      <title>Association of ODC genotypes with polyamine markers and treatment responses.</title>
                    </caption>
                    <alternatives>
                      <graphic id="pone.0127246.t006g" xlink:href="pone.0127246.t006"/>
                      <table frame="hsides" rules="groups">
                        <colgroup span="1">
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                          <col align="left" valign="middle" span="1"/>
                        </colgroup>
                        <thead>
                          <tr>
                            <th align="left" rowspan="1" colspan="1">ODC SNP</th>
                            <th colspan="3" align="center" rowspan="1">rs2302615</th>
                            <th colspan="3" align="center" rowspan="1">rs2302616</th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">Genotype</td>
                            <td align="left" rowspan="1" colspan="1">GG</td>
                            <td align="left" rowspan="1" colspan="1">Any A</td>
                            <td align="left" rowspan="1" colspan="1">P value</td>
                            <td align="left" rowspan="1" colspan="1">GG</td>
                            <td align="left" rowspan="1" colspan="1">Any T</td>
                            <td align="left" rowspan="1" colspan="1">P value</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">PFS</td>
                            <td align="left" rowspan="1" colspan="1">103 (67,NA)</td>
                            <td align="left" rowspan="1" colspan="1">62 (62,NA)</td>
                            <td align="char" char="." rowspan="1" colspan="1">0.51</td>
                            <td align="left" rowspan="1" colspan="1">64 (59,NA)</td>
                            <td align="left" rowspan="1" colspan="1">209 (62,NA)</td>
                            <td align="char" char="." rowspan="1" colspan="1">0.071</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">UPA C1D1</td>
                            <td align="left" rowspan="1" colspan="1">14.0 (7.9,24)</td>
                            <td align="left" rowspan="1" colspan="1">8.9 (5.4,12)</td>
                            <td align="char" char="." rowspan="1" colspan="1">0.67</td>
                            <td align="left" rowspan="1" colspan="1">7.9 (4.2,15)</td>
                            <td align="left" rowspan="1" colspan="1">16 (11,27)</td>
                            <td align="char" char="." rowspan="1" colspan="1">0.021</td>
                          </tr>
                          <tr>
                            <td align="left" rowspan="1" colspan="1">UPA (C1D1–C1D8)/ C1D1 X 100%</td>
                            <td align="left" rowspan="1" colspan="1">26 (-4.3,47)</td>
                            <td align="left" rowspan="1" colspan="1">-6.3 (-120,37)</td>
                            <td align="char" char="." rowspan="1" colspan="1">0.88</td>
                            <td align="left" rowspan="1" colspan="1">-27 (-130,13)</td>
                            <td align="left" rowspan="1" colspan="1">47 (35,61)</td>
                            <td align="char" char="." rowspan="1" colspan="1">0.0030</td>
                          </tr>
                        </tbody>
                      </table>
                    </alternatives>
                  </table-wrap>
                  <p>Urinary polyamines, especially DAS were also associated with disease progression. Urine samples were collected at intervals after baseline. For simplicity, <xref rid="pone.0127246.t005" ref-type="table">Table 5</xref> indicates whether DAS (or other urinary polyamine metabolites) increased from baseline values. Data was available from 17 of 18 patients evaluable for PFS. Baseline samples were not available for one patient in this group. Total urinary polyamines (putrescine+N<sup>1</sup>AcSpd+N<sup>8</sup>AcSpd+DAS) increased on average 6.56±16.29 μmol/g Creatinine from baseline in patients that experienced disease progression less than 100 days after start of therapy. Urinary polyamines decreased on average 1.57±3.37 μmol/g Creatinine in patients in whom disease progression occurred after 100 days from start of therapy. Urinary DAS increased in 9/10 patients with disease progression occurring within 100 days of therapy start, but in only 1/7 patients progression free up to 100 days (P = 0.056).</p>
                </sec>
              </sec>
              <sec id="sec021">
                <title>Response</title>
                <p>While this was a phase I study and was not powered to evaluate anti-tumor efficacy, tumor response and clinical response were monitored. Eighteen subjects were evaluable for efficacy following treatment. The response for patients after one cycle of DFMO alone included 12 patients with stable disease and 6 patients with progressive disease. Overall response, after treatment with both DFMO and etoposide, utilizing Response Evaluation Criteria In Solid Tumors (RECIST) criteria, MIBG evaluation and bone marrow disease showed; 1 patient had a best response of PR (MIBG evaluable disease only), 12 subjects has a best response of stable disease by RECIST (with 2 of these subjects having PR on MIBG and one subject having CR in bone marrow) and 5 had a best response of progressive disease. Three subjects were evaluated by PET scans, of which two had a complete response of PET activity and one a partial response, though PET scans were not routinely performed on all subjects. These 3 patients are those that remain without progression on this study. It should be noted that response attribution may be related to the incorporation of etoposide for patients during cycle 2–5. A Kaplan- Meier plot of progression-free survival (PFS) is shown in <xref rid="pone.0127246.g005" ref-type="fig">Fig 5</xref>. The median progression free survival for all 18 evaluable subjects was 80.5 (95% CI: 62–418) days. Three patients remain alive without progression of disease between 2–4.5 years after starting DFMO.</p>
                <fig id="pone.0127246.g005" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0127246.g005</object-id>
                  <label>Fig 5</label>
                  <caption>
                    <title>Progression free survival (PFS) and overall survival (OS) rates in patients enrolled in NMTRC 002 (N = 21).</title>
                    <p>The number of patients shown at risk for disease progression (PFS) or death (OS) is shown in the figure.</p>
                  </caption>
                  <graphic xlink:href="pone.0127246.g005"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec022">
              <title>Discussion</title>
              <p>This is the first clinical study of an oral dosing form of DFMO in any pediatric population. The recommended DFMO dose for Phase II studies is 500–1500 mg/m2 PO BID. The finding that this dose range is well tolerated by pediatric patients is notable. The results of this trial corroborate the safety of this agent noted in cancer chemoprevention studies in adults, where oral DFMO doses were 250–500 mg/m2 daily and ranged from 3–4 years in treatment duration [<xref rid="pone.0127246.ref046" ref-type="bibr">46</xref>, <xref rid="pone.0127246.ref047" ref-type="bibr">47</xref>]. Doses used in this trial, similar to adult dosing, were chosen using metronomic dosing to attain biological activity as shown by the decrease in urinary polyamines and responses seen. Therefore we did not dose escalate to define a maximum tolerated dose. The concept of metronomic therapy, using low-dose daily medications to target disease, is often better tolerated than high dose chemotherapy as seen in this patient population. There is increased interest in this method for extensively pretreated patients in which quality of life is an important consideration [<xref rid="pone.0127246.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0127246.ref048" ref-type="bibr">48</xref>, <xref rid="pone.0127246.ref049" ref-type="bibr">49</xref>].</p>
              <p>DFMO is a highly targeted therapy that selectively inhibits ODC and acts to suppress the synthesis of putrescine and the polyamines. The rationale for DFMO in NB is based in part on its role as an inhibitor downstream of MYCN, which is a major risk factor in this disease [<xref rid="pone.0127246.ref050" ref-type="bibr">50</xref>, <xref rid="pone.0127246.ref051" ref-type="bibr">51</xref>]. The results from this study suggest that genetic variability affecting ODC expression, specifically the rs2302616 SNP, is associated with increased polyamines, enhanced susceptibility to the ODC inhibitor DFMO and subsequent increased responsiveness to DFMO containing therapies in patients with NB. In this study response does not appear to be dependent on DFMO dose but rather correlates with genotype. These findings suggest that NBs in a subset of patients become “addicted” to polyamines in the manner suggested by Weinstein and colleagues for other cancer causing genes [<xref rid="pone.0127246.ref052" ref-type="bibr">52</xref>, <xref rid="pone.0127246.ref053" ref-type="bibr">53</xref>], and as such become susceptible to therapies targeting this addiction.</p>
              <p>In spite of these associations, some patients with the ODC risk allele did not respond to the DFMO plus etoposide therapy. It has been speculated that failures of therapies targeting single oncogenes are due to resistance mechanisms arising from acquisition of other activating mutations affecting additional signaling pathways [<xref rid="pone.0127246.ref053" ref-type="bibr">53</xref>]. Choi et al have recently reported evidence in support of this concept [<xref rid="pone.0127246.ref054" ref-type="bibr">54</xref>]. Their results suggest that DFMO combinations targeting other genetic features of NB [<xref rid="pone.0127246.ref055" ref-type="bibr">55</xref>–<xref rid="pone.0127246.ref057" ref-type="bibr">57</xref>] may be beneficial to patients not responding adequately to DFMO+/- etoposide.</p>
              <p>The PK findings in this work demonstrate that DFMO dosing in children yields serum DFMO concentrations that are very similar to those reported in adult studies, as the concentration ranges overlap, for equivalent oral doses [<xref rid="pone.0127246.ref058" ref-type="bibr">58</xref>] [<xref rid="pone.0127246.ref059" ref-type="bibr">59</xref>]. The Tmax values observed in NB patients were also comparable to the values reported in adults [<xref rid="pone.0127246.ref050" ref-type="bibr">50</xref>]. The finding that clinical benefit was observed for a number of patients in this study, along with the reported efficacy of DFMO at these concentrations in adult cancer prevention studies, indicates that biologically effective doses of DFMO are in the 50–150 μM range. DFMO doses in this range do not kill NB cells [<xref rid="pone.0127246.ref056" ref-type="bibr">56</xref>], suggesting other mechanisms of DFMO action. One non-cytotoxic mechanism described recently is the suppression of metabolites involved in DNA synthesis [<xref rid="pone.0127246.ref060" ref-type="bibr">60</xref>]. Other non-cytotoxic mechanisms could involve inflammation [<xref rid="pone.0127246.ref061" ref-type="bibr">61</xref>] and/or immune responses [<xref rid="pone.0127246.ref062" ref-type="bibr">62</xref>]. A recent publication suggests the promotion of tumor immunity by polyamine blockade in a T cell dependent manner [<xref rid="pone.0127246.ref063" ref-type="bibr">63</xref>].</p>
              <p>The secretion of polyamines in the urine as markers of neoplasia was proposed over 40 years ago [<xref rid="pone.0127246.ref064" ref-type="bibr">64</xref>]. Technology and limited understanding of the metabolism and transport of these polycationic molecules restricted their development. It is now appreciated that export of the polyamines is a highly regulated process, involving acetylation of spermidine and spermine, which enables them to act as counterions for a solute carrier transporter that facilitates arginine transport [<xref rid="pone.0127246.ref042" ref-type="bibr">42</xref>–<xref rid="pone.0127246.ref044" ref-type="bibr">44</xref>], as depicted in <xref rid="pone.0127246.g004" ref-type="fig">Fig 4</xref>. Substrates for the exporter of tissue polyamines has the general structure R<sub>1</sub>-NH<sub>2</sub>
<sup>+</sup>-(CH<sub>2</sub>)<sub>n&gt;2</sub>-NH<sub>2</sub>
<sup>+</sup>-R<sub>2</sub> [<xref rid="pone.0127246.ref042" ref-type="bibr">42</xref>]. Thus, putrescine, monoacetylspermidine and diacetylspermine, but neither spermidine nor spermine, are substrates for this exporter and might be expected to appear in the urine as a consequence of tissue attempts at homeostatic regulation under conditions of elevated polyamine metabolism. Spermidine, spermine and monoacetylspermine appear in the urine, but are likely either systemic degradation products resulting from cell lysis, serum amine oxidases (e.g. spermidine) or products of non-mammalian flora.</p>
              <p>We assessed the relevance of seven polyamine metabolites in the urine, including those that are substrates for the polyamine exporter SLC3A2 and include putrescine, N<sup>1</sup>AcSpd and N<sup>1</sup>, N<sup>12</sup>Ac<sub>2</sub>Spm. Only N<sup>1</sup>AcSpd was affected in a statistically significant manner by DFMO treatment during the first few weeks of therapy. This species is one of the most prevalent polyamine metabolites in urine and is notable in that it is targeted for export by acetylation by the SAT1 gene product, which is physically linked to the SLC3A2 exporter [<xref rid="pone.0127246.ref043" ref-type="bibr">43</xref>]. SAT1 also associates with ODC to form a potential metabolic channel for putrescine and polyamine synthesis and export.</p>
              <p>This is the first study to examine the polyamine titers in spot urine samples from NB patients. DFMO treatment reduced urinary N<sup>1</sup>AcSpd contents during the first two weeks of treatment in the population as a whole. Reductions in urinary polyamine levels were most significant in patients with the ODC minor T risk allele at rs2302616. Disease progression was associated with increases in urinary levels of especially DAS, although putrescine and monoacetylspermidine levels were elevated in some patients.</p>
              <p>Diacetylspermine has previously been identified as a marker for tumor progression in adults with colon and breast cancer [<xref rid="pone.0127246.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0127246.ref065" ref-type="bibr">65</xref>]. Although the NMTRC 002 study was a small study of 21 patients, urinary levels of polyamines, especially DAS appear to fluctuate with disease state and may be a marker of disease state that can be evaluated during therapy. These associations are currently under investigation in other phase I and II trials in patients with DFMO in NB within the NMTRC. These increases could reflect mechanisms of resistance including elevated ODC enzyme levels requiring increased amounts of DFMO. It should be noted that no obvious DFMO dose dependent responses were observed for either reductions of urinary polyamines or increases in PFS responses in this study. Subsequent studies investigating DFMO dose escalation in more detail are in progress.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec023">
              <title>Supporting Information</title>
              <supplementary-material content-type="local-data" id="pone.0127246.s001">
                <label>S1 Protocol</label>
                <caption>
                  <title>Study protocol.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0127246.s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0127246.s002">
                <label>S1 Table</label>
                <caption>
                  <title>Enrollment Characteristics and Previous Relapse Therapies prior to Enrollment.</title>
                  <p>(XLSX)</p>
                </caption>
                <media xlink:href="pone.0127246.s002.xlsx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0127246.s003">
                <label>S1 TREND Checklist</label>
                <caption>
                  <title>TREND checklist.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0127246.s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) supported this work in collaboration with Cancer Prevention Pharmaceuticals. This trial would not have been possible without the Beat NB Foundation, Max’s Ring of Fire, Meryl and Charles Witmer Foundation, Owen Moscone Foundation and many other families of children with neuroblastoma. This work was in part presented at the 104<sup>th</sup> Annual Meeting of the American Association for Cancer Research (AACR), April 6–10, 2013, Washington, DC, USA [<xref rid="pone.0127246.ref066" ref-type="bibr">66</xref>]. The help of Mr. David Stringer and Dr. Patricia Thompson in the PD studies is gratefully acknowledged. The work of Dr. Bonnie LaFleur, who did initial statistical analyses of the PD data, is also gratefully acknowledged. Dr. Patrick Shannon’s contributions to the PK studies are greatly appreciated.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0127246.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Maris</surname><given-names>JM</given-names></name>. <article-title>Recent advances in neuroblastoma</article-title>. <source>The New England journal of medicine</source>. <year>2010</year>;<volume>362</volume>(<issue>23</issue>):<fpage>2202</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra0804577</pub-id>
<?supplied-pmid 20558371?><pub-id pub-id-type="pmid">20558371</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>JR</given-names></name>, <name><surname>Bagatell</surname><given-names>R</given-names></name>, <name><surname>London</surname><given-names>WB</given-names></name>, <name><surname>Maris</surname><given-names>JM</given-names></name>, <name><surname>Cohn</surname><given-names>SL</given-names></name>, <name><surname>Mattay</surname><given-names>KK</given-names></name>, <etal>et al</etal><article-title>Children's Oncology Group's 2013 blueprint for research: neuroblastoma</article-title>. <source>Pediatric blood &amp; cancer</source>. <year>2013</year>;<volume>60</volume>(<issue>6</issue>):<fpage>985</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">23255319</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>AL</given-names></name>, <name><surname>Gilman</surname><given-names>AL</given-names></name>, <name><surname>Ozkaynak</surname><given-names>MF</given-names></name>, <name><surname>London</surname><given-names>WB</given-names></name>, <name><surname>Kreissman</surname><given-names>SG</given-names></name>, <name><surname>Chen</surname><given-names>HX</given-names></name>, <etal>et al</etal><article-title>Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma</article-title>. <source>The New England journal of medicine</source>. <year>2010</year>;<volume>363</volume>(<issue>14</issue>):<fpage>1324</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0911123</pub-id>
<?supplied-pmid 20879881?><pub-id pub-id-type="pmid">20879881</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Modak</surname><given-names>S</given-names></name>, <name><surname>Cheung</surname><given-names>NK</given-names></name>. <article-title>Neuroblastoma: Therapeutic strategies for a clinical enigma</article-title>. <source>Cancer treatment reviews</source>. <year>2010</year>;<volume>36</volume>(<issue>4</issue>):<fpage>307</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.ctrv.2010.02.006</pub-id>
<?supplied-pmid 20227189?><pub-id pub-id-type="pmid">20227189</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Bachmann</surname><given-names>AS</given-names></name>. <article-title>The role of polyamines in human cancer: prospects for drug combination therapies</article-title>. <source>Hawaii medical journal</source>. <year>2004</year>;<volume>63</volume>(<issue>12</issue>):<fpage>371</fpage>–<lpage>4</lpage>.
<?supplied-pmid 15704548?><pub-id pub-id-type="pmid">15704548</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Wallick</surname><given-names>CJ</given-names></name>, <name><surname>Gamper</surname><given-names>I</given-names></name>, <name><surname>Thorne</surname><given-names>M</given-names></name>, <name><surname>Feith</surname><given-names>DJ</given-names></name>, <name><surname>Takasaki</surname><given-names>KY</given-names></name>, <name><surname>Wilson</surname><given-names>SM</given-names></name>, <etal>et al</etal><article-title>Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells</article-title>. <source>Oncogene</source>. <year>2005</year>;<volume>24</volume>(<issue>36</issue>):<fpage>5606</fpage>–<lpage>18</lpage>.
<?supplied-pmid 16007177?><pub-id pub-id-type="pmid">16007177</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Koomoa</surname><given-names>DL</given-names></name>, <name><surname>Yco</surname><given-names>LP</given-names></name>, <name><surname>Borsics</surname><given-names>T</given-names></name>, <name><surname>Wallick</surname><given-names>CJ</given-names></name>, <name><surname>Bachmann</surname><given-names>AS</given-names></name>. <article-title>Ornithine Decarboxylase Inhibition by {alpha}-Difluoromethylornithine Activates Opposing Signaling Pathways via Phosphorylation of Both Akt/Protein Kinase B and p27Kip1 in Neuroblastoma</article-title>. <source>Cancer research</source>. <year>2008</year>;<volume>68</volume>(<issue>23</issue>):<fpage>9825</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1865</pub-id>
<?supplied-pmid 19047162?><pub-id pub-id-type="pmid">19047162</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Koomoa</surname><given-names>DL</given-names></name>, <name><surname>Geerts</surname><given-names>D</given-names></name>, <name><surname>Lange</surname><given-names>I</given-names></name>, <name><surname>Koster</surname><given-names>J</given-names></name>, <name><surname>Pegg</surname><given-names>AE</given-names></name>, <name><surname>Feith</surname><given-names>DJ</given-names></name>, <etal>et al</etal><article-title>DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma</article-title>. <source>Int J Oncol</source>. <year>2013</year>;<volume>42</volume>(<issue>4</issue>):<fpage>1219</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2013.1835</pub-id>
<?supplied-pmid 23440295?><pub-id pub-id-type="pmid">23440295</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Hogarty</surname><given-names>MD</given-names></name>, <name><surname>Norris</surname><given-names>MD</given-names></name>, <name><surname>Davis</surname><given-names>K</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Evageliou</surname><given-names>NF</given-names></name>, <name><surname>Hayes</surname><given-names>CS</given-names></name>, <etal>et al</etal><article-title>ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma</article-title>. <source>Cancer research</source>. <year>2008</year>;<volume>68</volume>(<issue>23</issue>):<fpage>9735</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6866</pub-id>
<?supplied-pmid 19047152?><pub-id pub-id-type="pmid">19047152</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Rounbehler</surname><given-names>RJ</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Hall</surname><given-names>MA</given-names></name>, <name><surname>Yang</surname><given-names>C</given-names></name>, <name><surname>Fallahi</surname><given-names>M</given-names></name>, <name><surname>Cleveland</surname><given-names>JL</given-names></name>. <article-title>Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma</article-title>. <source>Cancer research</source>. <year>2009</year>;<volume>69</volume>(<issue>2</issue>):<fpage>547</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2968</pub-id>
<?supplied-pmid 19147568?><pub-id pub-id-type="pmid">19147568</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Geerts</surname><given-names>D</given-names></name>, <name><surname>Koster</surname><given-names>J</given-names></name>, <name><surname>Albert</surname><given-names>D</given-names></name>, <name><surname>Koomoa</surname><given-names>DL</given-names></name>, <name><surname>Feith</surname><given-names>DJ</given-names></name>, <name><surname>Pegg</surname><given-names>AE</given-names></name>, <etal>et al</etal><article-title>The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification</article-title>. <source>International journal of cancer Journal international du cancer</source>. <year>2010</year>;<volume>126</volume>(<issue>9</issue>):<fpage>2012</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.25074</pub-id>
<?supplied-pmid 19960435?><pub-id pub-id-type="pmid">19960435</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Auvinen</surname><given-names>M</given-names></name>, <name><surname>Paasinen</surname><given-names>A</given-names></name>, <name><surname>Andersson</surname><given-names>LC</given-names></name>, <name><surname>Holtta</surname><given-names>E</given-names></name>. <article-title>Ornithine decarboxylase activity is critical for cell transformation</article-title>. <source>Nature</source>. <year>1992</year>;<volume>360</volume>(<issue>6402</issue>):<fpage>355</fpage>–<lpage>8</lpage>.
<?supplied-pmid 1280331?><pub-id pub-id-type="pmid">1280331</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Auvinen</surname><given-names>M</given-names></name>, <name><surname>Paasinen-Sohns</surname><given-names>A</given-names></name>, <name><surname>Hirai</surname><given-names>H</given-names></name>, <name><surname>Andersson</surname><given-names>LC</given-names></name>, <name><surname>Holtta</surname><given-names>E</given-names></name>. <article-title>Ornithine decarboxylase- and ras-induced cell transformations: reversal by protein tyrosine kinase inhibitors and role of pp130CAS</article-title>. <source>Molecular and cellular biology</source>. <year>1995</year>;<volume>15</volume>(<issue>12</issue>):<fpage>6513</fpage>–<lpage>25</lpage>.
<?supplied-pmid 8524216?><pub-id pub-id-type="pmid">8524216</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Auvinen</surname><given-names>M</given-names></name>, <name><surname>Jarvinen</surname><given-names>K</given-names></name>, <name><surname>Hotti</surname><given-names>A</given-names></name>, <name><surname>Okkeri</surname><given-names>J</given-names></name>, <name><surname>Laitinen</surname><given-names>J</given-names></name>, <name><surname>Janne</surname><given-names>OA</given-names></name>, <etal>et al</etal><article-title>Transcriptional regulation of the ornithine decarboxylase gene by c-Myc/Max/Mad network and retinoblastoma protein interacting with c-Myc</article-title>. <source>The international journal of biochemistry &amp; cell biology</source>. <year>2003</year>;<volume>35</volume>(<issue>4</issue>):<fpage>496</fpage>–<lpage>521</lpage>.<pub-id pub-id-type="pmid">12565711</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Lutz</surname><given-names>W</given-names></name>, <name><surname>Stohr</surname><given-names>M</given-names></name>, <name><surname>Schurmann</surname><given-names>J</given-names></name>, <name><surname>Wenzel</surname><given-names>A</given-names></name>, <name><surname>Lohr</surname><given-names>A</given-names></name>, <name><surname>Schwab</surname><given-names>M</given-names></name>. <article-title>Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells</article-title>. <source>Oncogene</source>. <year>1996</year>;<volume>13</volume>(<issue>4</issue>):<fpage>803</fpage>–<lpage>12</lpage>.
<?supplied-pmid 8761302?><pub-id pub-id-type="pmid">8761302</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Ben-Yosef</surname><given-names>T</given-names></name>, <name><surname>Yanuka</surname><given-names>O</given-names></name>, <name><surname>Halle</surname><given-names>D</given-names></name>, <name><surname>Benvenisty</surname><given-names>N</given-names></name>. <article-title>Involvement of Myc targets in c-myc and N-myc induced human tumors</article-title>. <source>Oncogene</source>. <year>1998</year>;<volume>17</volume>(<issue>2</issue>):<fpage>165</fpage>–<lpage>71</lpage>.
<?supplied-pmid 9674700?><pub-id pub-id-type="pmid">9674700</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>X</given-names></name>, <name><surname>Pearson</surname><given-names>A</given-names></name>, <name><surname>Lunec</surname><given-names>J</given-names></name>. <article-title>The MYCN oncoprotein as a drug development target</article-title>. <source>Cancer letters</source>. <year>2003</year>;<volume>197</volume>(<issue>1–2</issue>):<fpage>125</fpage>–<lpage>30</lpage>.
<?supplied-pmid 12880986?><pub-id pub-id-type="pmid">12880971</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref018">
                <label>18</label>
                <mixed-citation publication-type="book"><name><surname>Bachmann</surname><given-names>AS</given-names></name>, <name><surname>Geerts</surname><given-names>D</given-names></name>, <name><surname>Sholler</surname><given-names>G</given-names></name>. <chapter-title>Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention</chapter-title> In: <name><surname>Hayat</surname><given-names>MA</given-names></name>, editor. <source>Pediatric Cancer, Neuroblastoma: Diagnosis, Therapy, and Prognosis</source>. 1: <publisher-name>Springer</publisher-name>; <year>2012</year> p. <fpage>91</fpage>–<lpage>103</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Martinez</surname><given-names>ME</given-names></name>, <name><surname>O'Brien</surname><given-names>TG</given-names></name>, <name><surname>Fultz</surname><given-names>KE</given-names></name>, <name><surname>Babbar</surname><given-names>N</given-names></name>, <name><surname>Yerushalmi</surname><given-names>H</given-names></name>, <name><surname>Qu</surname><given-names>N</given-names></name>, <etal>et al</etal><article-title>Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2003</year>;<volume>100</volume>(<issue>13</issue>):<fpage>7859</fpage>–<lpage>64</lpage>.
<?supplied-pmid 12810952?><pub-id pub-id-type="pmid">12810952</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Visvanathan</surname><given-names>K</given-names></name>, <name><surname>Helzlsouer</surname><given-names>KJ</given-names></name>, <name><surname>Boorman</surname><given-names>DW</given-names></name>, <name><surname>Strickland</surname><given-names>PT</given-names></name>, <name><surname>Hoffman</surname><given-names>SC</given-names></name>, <name><surname>Comstock</surname><given-names>GW</given-names></name>, <etal>et al</etal><article-title>Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk</article-title>. <source>J Urol</source>. <year>2004</year>;<volume>171</volume>(<issue>2 Pt 1</issue>):<fpage>652</fpage>–<lpage>5</lpage>.
<?supplied-pmid 14713779?><pub-id pub-id-type="pmid">14713779</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>I</given-names></name>, <name><surname>Halliday</surname><given-names>S</given-names></name>, <name><surname>Greig</surname><given-names>H</given-names></name>, <name><surname>Heys</surname><given-names>SD</given-names></name>, <name><surname>Wallace</surname><given-names>HM</given-names></name>, <name><surname>Schofield</surname><given-names>AC</given-names></name>. <article-title>Genetic polymorphism in ornithine decarboxylase and risk of breast cancer</article-title>. <source>Fam Cancer</source>. <year>2009</year>;<volume>8</volume>(<issue>4</issue>):<fpage>307</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1007/s10689-009-9237-9</pub-id>
<?supplied-pmid 19225907?><pub-id pub-id-type="pmid">19225907</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Zell</surname><given-names>JA</given-names></name>, <name><surname>Ziogas</surname><given-names>A</given-names></name>, <name><surname>Ignatenko</surname><given-names>N</given-names></name>, <name><surname>Honda</surname><given-names>J</given-names></name>, <name><surname>Qu</surname><given-names>N</given-names></name>, <name><surname>Bobbs</surname><given-names>AS</given-names></name>, <etal>et al</etal><article-title>Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival</article-title>. <source>Clin Cancer Res</source>. <year>2009</year>;<volume>15</volume>(<issue>19</issue>):<fpage>6208</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0592</pub-id>
<?supplied-pmid 19789310?><pub-id pub-id-type="pmid">19789310</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Norris</surname><given-names>MDG</given-names></name>, <name><surname>Purgato</surname><given-names>S</given-names></name>, <name><surname>Valli</surname><given-names>E</given-names></name>, <name><surname>Rihani</surname><given-names>A</given-names></name>, <name><surname>Van Maerken</surname><given-names>T</given-names></name>, <name><surname>Vandesompele</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>The ornithine decarboxylase G317A polymorphism is prognostic of outcome in primary neuroblastoma and differentially affects promoter binding by the MYCN oncogene</article-title>. <source>Advances in Neuroblastoma Research</source>. <year>2014</year>;Abstract OR059:<fpage>140</fpage>.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Garcia-Huidobro</surname><given-names>JM</given-names></name>, <name><surname>Brooks</surname><given-names>T</given-names></name>, <name><surname>Gerner</surname><given-names>EW</given-names></name>. <article-title>Functional consequence of genetic variability in a G-quadruplex structure in the ornithine decarboxylase (odc1) gene</article-title>. <source>Nucleic Acids Research</source>. <year>2014</year>;submitted.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Garcia-Huidobro</surname><given-names>JT</given-names></name>, <name><surname>Wertheim</surname><given-names>BC</given-names></name>, <name><surname>Gerner</surname><given-names>EW</given-names></name>. <article-title>Intron 1 polymorphisms cooperate to modulate odc1 transcriptional activity and risk of colorectal adenomas</article-title>. <source>Cancer research</source>. <year>2014</year>;submitted.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Casero</surname><given-names>RA</given-names><suffix>Jr.</suffix></name>, <name><surname>Marton</surname><given-names>LJ</given-names></name>. <article-title>Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases</article-title>. <source>Nature reviews Drug discovery</source>. <year>2007</year>;<volume>6</volume>(<issue>5</issue>):<fpage>373</fpage>–<lpage>90</lpage>.
<?supplied-pmid 17464296?><pub-id pub-id-type="pmid">17464296</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Pegg</surname><given-names>AE</given-names></name>, <name><surname>Feith</surname><given-names>DJ</given-names></name>. <article-title>Polyamines and neoplastic growth</article-title>. <source>Biochemical Society transactions</source>. <year>2007</year>;<volume>35</volume>(<issue>Pt 2</issue>):<fpage>295</fpage>–<lpage>9</lpage>.
<?supplied-pmid 17371264?><pub-id pub-id-type="pmid">17371264</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Priotto</surname><given-names>G</given-names></name>, <name><surname>Kasparian</surname><given-names>S</given-names></name>, <name><surname>Mutombo</surname><given-names>W</given-names></name>, <name><surname>Ngouama</surname><given-names>D</given-names></name>, <name><surname>Ghorashian</surname><given-names>S</given-names></name>, <name><surname>Arnold</surname><given-names>U</given-names></name>, <etal>et al</etal><article-title>Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>374</volume>(<issue>9683</issue>):<fpage>56</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(09)61117-X</pub-id>
<?supplied-pmid 19559476?><pub-id pub-id-type="pmid">19559476</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Alirol</surname><given-names>E</given-names></name>, <name><surname>Schrumpf</surname><given-names>D</given-names></name>, <name><surname>Amici Heradi</surname><given-names>J</given-names></name>, <name><surname>Riedel</surname><given-names>A</given-names></name>, <name><surname>de Patoul</surname><given-names>C</given-names></name>, <name><surname>Quere</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Medecins Sans Frontieres experience in the Democratic Republic of the Congo</article-title>. <source>Clinical infectious diseases: an official publication of the Infectious Diseases Society of America</source>. <year>2013</year>;<volume>56</volume>(<issue>2</issue>):<fpage>195</fpage>–<lpage>203</lpage>.<pub-id pub-id-type="pmid">23074318</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Blume-Peytavi</surname><given-names>U</given-names></name>, <name><surname>Hahn</surname><given-names>S</given-names></name>. <article-title>Medical treatment of hirsutism</article-title>. <source>Dermatologic therapy</source>. <year>2008</year>;<volume>21</volume>(<issue>5</issue>):<fpage>329</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1111/j.1529-8019.2008.00215.x</pub-id>
<?supplied-pmid 18844711?><pub-id pub-id-type="pmid">18844711</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Kushner</surname><given-names>BH</given-names></name>, <name><surname>Kramer</surname><given-names>K</given-names></name>, <name><surname>Cheung</surname><given-names>NK</given-names></name>. <article-title>Oral etoposide for refractory and relapsed neuroblastoma</article-title>. <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source>. <year>1999</year>;<volume>17</volume>(<issue>10</issue>):<fpage>3221</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">10506622</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Dorr</surname><given-names>RT</given-names></name>, <name><surname>Liddil</surname><given-names>JD</given-names></name>, <name><surname>Gerner</surname><given-names>EW</given-names></name>. <article-title>Modulation of etoposide cytotoxicity and DNA strand scission in L1210 and 8226 cells by polyamines</article-title>. <source>Cancer research</source>. <year>1986</year>;<volume>46</volume>(<issue>8</issue>):<fpage>3891</fpage>–<lpage>5</lpage>.
<?supplied-pmid 3015379?><pub-id pub-id-type="pmid">3015379</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Thompson</surname><given-names>PA</given-names></name>, <name><surname>Wertheim</surname><given-names>BC</given-names></name>, <name><surname>Zell</surname><given-names>JA</given-names></name>, <name><surname>Chen</surname><given-names>WP</given-names></name>, <name><surname>McLaren</surname><given-names>CE</given-names></name>, <name><surname>LaFleur</surname><given-names>BJ</given-names></name>, <etal>et al</etal><article-title>Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma</article-title>. <source>Gastroenterology</source>. <year>2010</year>;<volume>139</volume>(<issue>3</issue>):<fpage>797</fpage>–<lpage>805</lpage>, <fpage>e1</fpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2010.06.005</pub-id>
<?supplied-pmid 20538001?><pub-id pub-id-type="pmid">20538001</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Kawakita</surname><given-names>M</given-names></name>, <name><surname>Hiramatsu</surname><given-names>K</given-names></name>, <name><surname>Yanagiya</surname><given-names>M</given-names></name>, <name><surname>Doi</surname><given-names>Y</given-names></name>, <name><surname>Kosaka</surname><given-names>M</given-names></name>. <article-title>Determination of N(1),N(1)(2)-diacetylspermine in urine: a novel tumor marker</article-title>. <source>Methods in molecular biology</source>. <year>2011</year>;<volume>720</volume>:<fpage>367</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-61779-034-8_23</pub-id>
<?supplied-pmid 21318886?><pub-id pub-id-type="pmid">21318886</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref035">
                <label>35</label>
                <mixed-citation publication-type="book"><name><surname>Kablfleisch</surname><given-names>RL</given-names></name>. <source>The Statistical Analysis of Failure Time Data</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Wiley</publisher-name>; <year>1980</year>.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref036">
                <label>36</label>
                <mixed-citation publication-type="other">Team RC. R: A language and environment for statistical computing. Vienna, Austria2014. Available: <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref037">
                <label>37</label>
                <mixed-citation publication-type="other">T T. _A Package for Survival Analysis in S_. R package version 2.37–7 ed2014.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref038">
                <label>38</label>
                <mixed-citation publication-type="book"><name><surname>Therneau</surname><given-names>TM</given-names></name>, <name><surname>Grambsch</surname><given-names>PM</given-names></name>. <source>Modeling survival data: extending the Cox model</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2000</year><fpage>xiii</fpage>, <fpage>350</fpage> p. p.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Harrington</surname><given-names>TR.</given-names></name>. <article-title>A class of rank test procedures for censored survival data</article-title>. <source>Biometrika</source><year>1982</year>;<volume>69</volume>:<fpage>553</fpage>–<lpage>66</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref040">
                <label>40</label>
                <mixed-citation publication-type="book"><name><surname>Davison</surname><given-names>AC</given-names></name>, <name><surname>Hinkley</surname><given-names>DV</given-names></name>. <source>Bootstrap methods and their application</source>. <publisher-loc>Cambridge; New York, NY, USA</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>; <year>1997</year><fpage>x</fpage>, <fpage>582</fpage> p. p.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref041">
                <label>41</label>
                <mixed-citation publication-type="other">Ripley ACaB. boot: Bootstrap R (S-Plus) Functions. 2015.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>X</given-names></name>, <name><surname>Gillies</surname><given-names>RJ</given-names></name>, <name><surname>Gerner</surname><given-names>EW</given-names></name>. <article-title>Characterization of a diamine exporter in Chinese hamster ovary cells and identification of specific polyamine substrates</article-title>. <source>J Biol Chem</source>. <year>1997</year>;<volume>272</volume>(<issue>33</issue>):<fpage>20484</fpage>–<lpage>9</lpage>.
<?supplied-pmid 9252359?><pub-id pub-id-type="pmid">9252359</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Uemura</surname><given-names>T</given-names></name>, <name><surname>Yerushalmi</surname><given-names>HF</given-names></name>, <name><surname>Tsaprailis</surname><given-names>G</given-names></name>, <name><surname>Stringer</surname><given-names>DE</given-names></name>, <name><surname>Pastorian</surname><given-names>KE</given-names></name>, <name><surname>Hawel</surname><given-names>L</given-names><suffix>3rd</suffix></name>, <etal>et al</etal><article-title>Identification and characterization of a diamine exporter in colon epithelial cells</article-title>. <source>J Biol Chem</source>. <year>2008</year>;<volume>283</volume>(<issue>39</issue>):<fpage>26428</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M804714200</pub-id>
<?supplied-pmid 18660501?><pub-id pub-id-type="pmid">18660501</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Uemura</surname><given-names>T</given-names></name>, <name><surname>Stringer</surname><given-names>DE</given-names></name>, <name><surname>Blohm-Mangone</surname><given-names>KA</given-names></name>, <name><surname>Gerner</surname><given-names>EW</given-names></name>. <article-title>Polyamine transport is mediated by both endocytic and solute carrier transport mechanisms in the gastrointestinal tract</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2010</year>;<volume>299</volume>(<issue>2</issue>):<fpage>G517</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.00169.2010</pub-id>
<?supplied-pmid 20522643?><pub-id pub-id-type="pmid">20522643</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref045">
                <label>45</label>
                <mixed-citation publication-type="journal"><name><surname>Gerner</surname><given-names>EW</given-names></name>, <name><surname>Meyskens</surname><given-names>FL</given-names><suffix>Jr</suffix></name>. <article-title>Polyamines and cancer: old molecules, new understanding</article-title>. <source>Nature Reviews Cancer</source>. <year>2004</year>;<volume>4</volume>(<issue>10</issue>):<fpage>781</fpage>–<lpage>92</lpage>.
<?supplied-pmid 15510159?><pub-id pub-id-type="pmid">15510159</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref046">
                <label>46</label>
                <mixed-citation publication-type="journal"><name><surname>Meyskens</surname><given-names>FL</given-names><suffix>Jr.</suffix></name>, <name><surname>McLaren</surname><given-names>CE</given-names></name>, <name><surname>Pelot</surname><given-names>D</given-names></name>, <name><surname>Fujikawa-Brooks</surname><given-names>S</given-names></name>, <name><surname>Carpenter</surname><given-names>PM</given-names></name>, <name><surname>Hawk</surname><given-names>E</given-names></name>, <etal>et al</etal><article-title>Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial</article-title>. <source>Cancer prevention research</source>. <year>2008</year>;<volume>1</volume>(<issue>1</issue>):<fpage>32</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-08-0042</pub-id>
<?supplied-pmid 18841250?><pub-id pub-id-type="pmid">18841250</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref047">
                <label>47</label>
                <mixed-citation publication-type="journal"><name><surname>Bailey</surname><given-names>HH</given-names></name>, <name><surname>Kim</surname><given-names>K</given-names></name>, <name><surname>Verma</surname><given-names>AK</given-names></name>, <name><surname>Sielaff</surname><given-names>K</given-names></name>, <name><surname>Larson</surname><given-names>PO</given-names></name>, <name><surname>Snow</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer</article-title>. <source>Cancer prevention research</source>. <year>2010</year>;<volume>3</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-09-0096</pub-id>
<?supplied-pmid 20051371?><pub-id pub-id-type="pmid">20051371</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref048">
                <label>48</label>
                <mixed-citation publication-type="journal"><name><surname>Kareva</surname><given-names>I</given-names></name>, <name><surname>Waxman</surname><given-names>DJ</given-names></name>, <name><surname>Klement</surname><given-names>GL</given-names></name>. <article-title>Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance</article-title>. <source>Cancer letters</source>. <year>2014</year>.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref049">
                <label>49</label>
                <mixed-citation publication-type="journal"><name><surname>Robison</surname><given-names>NJ</given-names></name>, <name><surname>Campigotto</surname><given-names>F</given-names></name>, <name><surname>Chi</surname><given-names>SN</given-names></name>, <name><surname>Manley</surname><given-names>PE</given-names></name>, <name><surname>Turner</surname><given-names>CD</given-names></name>, <name><surname>Zimmerman</surname><given-names>MA</given-names></name>, <etal>et al</etal><article-title>A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer</article-title>. <source>Pediatric blood &amp; cancer</source>. <year>2014</year>;<volume>61</volume>(<issue>4</issue>):<fpage>636</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">24123865</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref050">
                <label>50</label>
                <mixed-citation publication-type="journal"><name><surname>Evageliou</surname><given-names>NF</given-names></name>, <name><surname>Hogarty</surname><given-names>MD</given-names></name>. <article-title>Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma</article-title>. <source>Clin Cancer Res</source>. <year>2009</year>;<volume>15</volume>(<issue>19</issue>):<fpage>5956</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-3213</pub-id>
<?supplied-pmid 19789308?><pub-id pub-id-type="pmid">19789308</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref051">
                <label>51</label>
                <mixed-citation publication-type="journal"><name><surname>Gamble</surname><given-names>LD</given-names></name>, <name><surname>Hogarty</surname><given-names>MD</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Ziegler</surname><given-names>DS</given-names></name>, <name><surname>Marshall</surname><given-names>G</given-names></name>, <name><surname>Norris</surname><given-names>MD</given-names></name>, <etal>et al</etal><article-title>Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma</article-title>. <source>Frontiers in oncology</source>. <year>2012</year>;<volume>2</volume>:<fpage>162</fpage><pub-id pub-id-type="doi">10.3389/fonc.2012.00162</pub-id><?supplied-pmid 23181218?><pub-id pub-id-type="pmid">23181218</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref052">
                <label>52</label>
                <mixed-citation publication-type="journal"><name><surname>Weinstein</surname><given-names>IB</given-names></name>, <name><surname>Joe</surname><given-names>AK</given-names></name>. <article-title>Mechanisms of disease: Oncogene addiction—a rationale for molecular targeting in cancer therapy</article-title>. <source>Nature clinical practice Oncology</source>. <year>2006</year>;<volume>3</volume>(<issue>8</issue>):<fpage>448</fpage>–<lpage>57</lpage>.
<?supplied-pmid 16894390?><pub-id pub-id-type="pmid">16894390</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref053">
                <label>53</label>
                <mixed-citation publication-type="journal"><name><surname>Weinstein</surname><given-names>IB</given-names></name>, <name><surname>Joe</surname><given-names>A</given-names></name>. <article-title>Oncogene addiction</article-title>. <source>Cancer research</source>. <year>2008</year>;<volume>68</volume>(<issue>9</issue>):<fpage>3077</fpage>–<lpage>80</lpage>; discussion 80. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-3293</pub-id>
<?supplied-pmid 18451130?><pub-id pub-id-type="pmid">18451130</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref054">
                <label>54</label>
                <mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>PS</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Felsher</surname><given-names>DW</given-names></name>. <article-title>Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2014</year>.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref055">
                <label>55</label>
                <mixed-citation publication-type="journal"><name><surname>Pugh</surname><given-names>TJ</given-names></name>, <name><surname>Morozova</surname><given-names>O</given-names></name>, <name><surname>Attiyeh</surname><given-names>EF</given-names></name>, <name><surname>Asgharzadeh</surname><given-names>S</given-names></name>, <name><surname>Wei</surname><given-names>JS</given-names></name>, <name><surname>Auclair</surname><given-names>D</given-names></name>, <etal>et al</etal><article-title>The genetic landscape of high-risk neuroblastoma</article-title>. <source>Nature genetics</source>. <year>2013</year>;<volume>45</volume>(<issue>3</issue>):<fpage>279</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2529</pub-id>
<?supplied-pmid 23334666?><pub-id pub-id-type="pmid">23334666</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref056">
                <label>56</label>
                <mixed-citation publication-type="journal"><name><surname>Samal</surname><given-names>K</given-names></name>, <name><surname>Zhao</surname><given-names>P</given-names></name>, <name><surname>Kendzicky</surname><given-names>A</given-names></name>, <name><surname>Yco</surname><given-names>LP</given-names></name>, <name><surname>McClung</surname><given-names>H</given-names></name>, <name><surname>Gerner</surname><given-names>EW</given-names></name>, <etal>et al</etal><article-title>AMXT-15, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting cell proliferation by targeting both ornithine decarboxylase and polyamine transport</article-title>. <source>International Journal of Cancer</source>. <year>2013</year>;accepted.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref057">
                <label>57</label>
                <mixed-citation publication-type="journal"><name><surname>Lange</surname><given-names>I</given-names></name>, <name><surname>Geerts</surname><given-names>D</given-names></name>, <name><surname>Feith</surname><given-names>DJ</given-names></name>, <name><surname>Mocz</surname><given-names>G</given-names></name>, <name><surname>Koster</surname><given-names>J</given-names></name>, <name><surname>Bachmann</surname><given-names>AS</given-names></name>. <article-title>Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation</article-title>. <source>Journal of molecular biology</source>. <year>2014</year>;<volume>426</volume>(<issue>2</issue>):<fpage>332</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2013.09.037</pub-id>
<?supplied-pmid 24096079?><pub-id pub-id-type="pmid">24096079</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref058">
                <label>58</label>
                <mixed-citation publication-type="journal"><name><surname>Pendyala</surname><given-names>L</given-names></name>, <name><surname>Creaven</surname><given-names>PJ</given-names></name>, <name><surname>Porter</surname><given-names>CW</given-names></name>. <article-title>Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial</article-title>. <source>Cancer epidemiology, biomarkers &amp; prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</source>. <year>1993</year>;<volume>2</volume>(<issue>3</issue>):<fpage>235</fpage>–<lpage>41</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0127246.ref059">
                <label>59</label>
                <mixed-citation publication-type="journal"><name><surname>Carbone</surname><given-names>PP</given-names></name>, <name><surname>Douglas</surname><given-names>JA</given-names></name>, <name><surname>Thomas</surname><given-names>J</given-names></name>, <name><surname>Tutsch</surname><given-names>K</given-names></name>, <name><surname>Pomplun</surname><given-names>M</given-names></name>, <name><surname>Hamielec</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine</article-title>. <source>Clinical Cancer Research</source>. <year>2000</year>;<volume>6</volume>(<issue>10</issue>):<fpage>3850</fpage>–<lpage>4</lpage>.
<?supplied-pmid 11051229?><pub-id pub-id-type="pmid">11051229</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref060">
                <label>60</label>
                <mixed-citation publication-type="journal"><name><surname>Witherspoon</surname><given-names>M</given-names></name>, <name><surname>Chen</surname><given-names>Q</given-names></name>, <name><surname>Kopelovich</surname><given-names>L</given-names></name>, <name><surname>Gross</surname><given-names>SS</given-names></name>, <name><surname>Lipkin</surname><given-names>SM</given-names></name>. <article-title>Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by alpha-difluoromethylornithine</article-title>. <source>Cancer discovery</source>. <year>2013</year>;<volume>3</volume>(<issue>9</issue>):<fpage>1072</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0305</pub-id>
<?supplied-pmid 23771434?><pub-id pub-id-type="pmid">23771434</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref061">
                <label>61</label>
                <mixed-citation publication-type="journal"><name><surname>Babbar</surname><given-names>N</given-names></name>, <name><surname>Murray-Stewart</surname><given-names>T</given-names></name>, <name><surname>Casero</surname><given-names>RA</given-names><suffix>Jr</suffix></name>. <article-title> Inflammation and polyamine catabolism: the good, the bad and the ugly</article-title>. <source>Biochemical Society transactions</source>. <year>2007</year>;<volume>35</volume>(<issue>Pt 2</issue>):<fpage>300</fpage>–<lpage>4</lpage>.
<?supplied-pmid 17371265?><pub-id pub-id-type="pmid">17371265</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref062">
                <label>62</label>
                <mixed-citation publication-type="journal"><name><surname>Soda</surname><given-names>K</given-names></name>. <article-title>The mechanisms by which polyamines accelerate tumor spread</article-title>. <source>Journal of experimental &amp; clinical cancer research: CR</source>. <year>2011</year>;<volume>30</volume>:<fpage>95</fpage>.<pub-id pub-id-type="pmid">21988863</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref063">
                <label>63</label>
                <mixed-citation publication-type="journal"><name><surname>Hayes</surname><given-names>CS</given-names></name>, <name><surname>Burns</surname><given-names>MR</given-names></name>, <name><surname>Gilmour</surname><given-names>SK</given-names></name>. <article-title>Polyamine blockade promotes antitumor immunity</article-title>. <source>Oncoimmunology</source>. <year>2014</year>;<volume>3</volume>(<issue>1</issue>):<fpage>e27360</fpage><?supplied-pmid 24711956?><pub-id pub-id-type="pmid">24711956</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref064">
                <label>64</label>
                <mixed-citation publication-type="journal"><name><surname>Russell</surname><given-names>DH</given-names></name>, <name><surname>Levy</surname><given-names>CC</given-names></name>. <article-title>Polyamine accumulation and biosynthesis in a mouse L1210 leukemia</article-title>. <source>Cancer research</source>. <year>1971</year>;<volume>31</volume>(<issue>3</issue>):<fpage>248</fpage>–<lpage>51</lpage>.
<?supplied-pmid 5547211?><pub-id pub-id-type="pmid">5547211</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref065">
                <label>65</label>
                <mixed-citation publication-type="journal"><name><surname>Hiramatsu</surname><given-names>K</given-names></name>, <name><surname>Takahashi</surname><given-names>K</given-names></name>, <name><surname>Yamaguchi</surname><given-names>T</given-names></name>, <name><surname>Matsumoto</surname><given-names>H</given-names></name>, <name><surname>Miyamoto</surname><given-names>H</given-names></name>, <name><surname>Tanaka</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers</article-title>. <source>Clinical Cancer Research</source>. <year>2005</year>;<volume>11</volume>(<issue>8</issue>):<fpage>2986</fpage>–<lpage>90</lpage>.
<?supplied-pmid 15837752?><pub-id pub-id-type="pmid">15837752</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0127246.ref066">
                <label>66</label>
                <mixed-citation publication-type="journal"><name><surname>Sholler</surname><given-names>GL</given-names></name>. <article-title>A Phase 1 Trial of DFMO as a Single Agent and in Combination with Etoposide in Patients with Refractory or Recurrent Neuroblastoma</article-title>. <source>Proc AACR</source>. <year>2013</year>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
